Clinical Oncology Research Group

The Clinical Oncology Research Group (GOC) was created in 2021.
Its main mission is to create a group of scientifically robust and capable elements among different health professionals.
GOC projects seek to answer clinical questions resulting from real needs, by analyzing real-life data, to continuously improve the quality of treatment offered to patients.
Although recent, the GOC team has been expanding, integrating elements that have invested in their academic progression and elements that have completed clinical internships at internationally renowned oncology centers, such as the MD Anderson Cancer Center and Gustave Roussy.
The multidisciplinary nature of its elements is a differentiating characteristic and promotes stimulating, fruitful and advantageous discussions for scientific research. Its members are committed to the group’s mission.

 

SCIENTIFIC COORDINATOR

Ana Espírito Santo, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-4840-590X/ DA1B-35B9-E2D4
Consultant Clinical Hematologist
Email: ana.esanto@ipoporto.min-saude.pt

TEAM
Senior Researchers

Cláudia Vieira, MD, PhD
ORCID ID/ Ciência ID: 0000-0001-5396-9753/ 641E-265C-9730
Consultant Medical Oncologist
Email: claudia.vieira@ipoporto.min-saude.pt

Magda Andrea Silva Oliveira, PhD
ORCID ID/ Ciência ID: 0000-0002-0653-341X/ E614-C685-6817
Psychologist
Email: magda.oliveira@ipoporto.min-saude.pt

Maria Deolinda Pereira, MD, PhD
ORCID ID/ Ciência ID: 0000-0003-2367-1299/ 991B-E677-158E
Senior Consultant Medical Oncologist
Email: dpereira@ipoporto.min-saude.pt

Mavilde Rodrigues Arantes da Silva Longarito, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-0297-2247/ 6E17-7D72-53E7
Consultant Neuroradiologist
Email: i11815@ipoporto.min-saude.pt

Miguel Henriques Abreu, MD, PhD
ORCID ID/ Ciência ID: 0000-0003-3940-0688/ F61D-1E69-3148
Consultant Medical Oncologist
Email: antonio.m.abreu@ipoporto.min-saude.pt

Joaquim Castro Silva, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-3934-9950/ B418-68AE-3A6A
Consultant Otorrinolaringologist
Email: joaquim.castro@ipoporto.min-saude.pt

Jorge Serafim Sobrado Marinho, MD, PhD
ORCID ID/ Ciência ID: 0000-0003-1222-627X/ 311C-6EF7-EB13
Consultant Stomatologist
Email: jmarinho@ipoporto.min-saude.pt

Guest Researchers

Rita Ribeiro Silva, PhD
ORCID ID/ Ciência ID:
Attending Clinical Hematologist @
Email: rita.rbsilva@gmail.com

PhD Students

Daniela Rocha-Santos, MSc (with ETPG)
ORCID ID/ Ciência ID: 0000-0003-1081-5142/ 4617-DBEA-8AE6
Email: daniela.r.santos@ipoporto.min-saude.pt

José Manuel Ferrer Martinez, BSN, MSc; Specialist nurse
ORCID ID/ Ciência ID: 0000-0002-7909-7938/ DF1B-A0A1-2302
Email: jmmartinez@ipoporto.min-saude.pt

Pedro Miguel dos Reis Cruz, MD, MSc Resident in Medical Oncology (with ETPG)
ORCID ID/ Ciência ID: 0000-0001-8813-0632/ 0610-621F-B88A
Email: pedro.reis.cruz@ipoporto.min-saude.pt

Valéria Delgado Tavares, MSc (with MOVPG)
ORCID ID/ Ciência ID: 0000-0003-3680-7757/ B715-3863-A1DA
Email: valeria.tavares@ipoporto.min-saude.pt

Other collaborators

Alina Rosinha, MD, MSc, Attending Medical Oncologist
Ana Alexandra Ferreira, MD, BSc, Consultant Medical Oncologist
Ana Filipa Carneiro, MD, BSc Attending Medical Oncologist
Ana Isabel Vaz Ferreira MD, MSc, Resident in Medical Oncology
Ana Maria Meireles MD, MSc,Resident in Clinical Hematology
Ana Raquel Teixeira MD, MSc, Resident in Medical Oncology
Ana Rita Lopes MD, MSc; Attending Medical Oncologist
Ana Sofia Jardim Patrão MD, MSc; Attending Medical Oncologist
Andreia Guimarães da Cruz, MD, MSc, Attending Medical Oncologist
Cátia Faustino, MD, BSc, Consultant Medical Oncologist
Cláudia Melissa de Paiva Agostinho MD, MSc, Resident in Medical Oncology
Cláudia Sílvia da Rocha Moreira, MD, BSc, Attending Clinical Hematologist
Dânia Sofia Marques Santos, MD, MSc Consultant Medical Oncologist
Dulcineia José Nunes de Alves Pereira, MD, BSc Attending Hemato-oncologist
Hugo André do Nascimento Ferreira, MD, MSc; Attending Nefrologist
Inês Baptista Freitas, MD, MSc, Resident in Medical Oncology
Joana Savva Bordalo e Sa, MD, MSc Consultant Medical Oncologist
João Pedro Gouveia da Fonseca, MD, MSc; Resident in Medical Oncology
José Brito da Silva, MD, MSc; Resident in Medical Oncology
Maria Cândida Silva, MD, MSc; Attending General and Family Medicine
Maria Gabriela Martins, MD, BSc; Consultant Medical Oncologist
Maria Isabel Vilas-Boas, MD, MSc; Attending Medical Oncologist
Maria Joaquina Maurício, MD, MSc; Senior Consultant Medical Oncologist
Maria Cassiano Neves, MD, BSc; Consultant Medical Oncologist
Marta Soares, MD, BSc, Senior Consultant Medical Oncologist
Marta Isabel Ribeiro Ferreira, MD, MSc; Consultant Medical Oncologist
Michael Sapateiro Luís, MD, MSc; Consultant Medical Oncologist
Nuno Duarte Gonçalves, MD, BSc; Senior Consult Clinical Patologist
Olga Dulce Sousa de Meneses, MD, MSc; Resident in Medical Oncology
Paula Cristina da Silva Ferreira, MD, BSc; Consultant Medical Oncologist
Rita Amorim e Costa, MD, MSc; Resident in Medical Oncology
Rute Fernandes, MD, MSc; Resident in Medical Oncology
Sara Cristina Neves de Carvalho, MD, MSc; Resident in Medical Oncology
Sara Marina Carneiro Pinto Coelho, MD, MSc Attending Medical Oncologist
Susana Sousa Almeida, MD, MSc; Senior Consultant Psychiatrist
Vítor Costa, MD, BSc Attending Pediatrician

Aims

The main objective of the GOC is to establish bridges between clinical practice and translational research, in order to allow patients access to more efficient and innovative treatments.
The GOC encourages clinical studies of research initiative and promotes collaborative efforts both internally, with other groups at the Research Center, but also externally through partnerships with national and international organizations.
A cornerstone of the GOC is encouraging the continuous training of health professionals, with a focus on improving the quality of care provided to cancer patients.

PROJECTS WITH EXTERNAL FUNDING

Epidemiological characterization of the population of patients with chronic myeloid leukemia treated at the Porto IPO – Portuguese Association Against Leukemia, Portuguese Society of Hematology and Novartis; 15 000 € (2023); Dr. Ana Meireles (PI)

The introduction of tyrosine kinase inhibitors (TKI) was revolutionary in the treatment of chronic myeloid leukemia (CML). The focus changed from delaying the progression of the disease to more advanced stages, to obtaining a survival similar to the general population, achieving a profound molecular response and discontinuing therapy while maintaining remission. Furthermore, it is increasingly important to consider the effects of TKIs on patients’ quality of life and patient-reported outcomes in the therapeutic approach. There are several studies on responses and adverse effects in patients with CML. However, the characterization of these patients in Portugal is not yet known. This project’s main objective is to describe the population of patients with CML treated at IPOP and, in parallel, to describe adverse effects of TKIs documented in these patients and which patients are candidates for TKI suspension and whether there was a need to resume TKIs.

FAROL – Implementation of a financing model based on the measurement of clinical and non-clinical outcomes and integrated disease management in lung cancer at IPO Porto; (2018-2023); Dr. Marta Soares (PI)

The FAROL pilot project, focusing on Health Results and Integrated Disease Management, consists of developing a financing model focused on measuring results with incentives associated with quality.

CHIP-AML22 – Improved diagnostics and survival for all children with Acute Myeloid Leukemia treated within the NOPHO-DB- SHIP consortium; a cross-European collaboration;193 481,68€ (2022-2025); Dr. Vítor Costa (PI @ IPO Porto)

The CHIP-AML22 project seeks to implement new diagnostic techniques for Acute Myeloid Leukemia (AML) to improve the treatment of patients with these diseases. This consortium seeks to:

– Perform the genetic profile of AML cells to better stratify the risk group of patients.

-WGS and RNA seq analysis to incorporate and improve patient treatment;

– The implementation and evaluation of the response to treatment of both methods during and after treatment, across the consortium.

HENKO NET – Innovation and Digital Technologies for Social and Health Palliative Care at home; 157 886,96€ (2024-2026); Dr. Maria Paula Silva (PI @ IPO Porto)

In several European countries such as Spain, France and Portugal, only a portion of people in need of palliative care (PC) actually receive it.

However, PC are essential in controlling symptoms, providing relief, and respecting people’s dignity and as such are an ethical obligation. The significant number of patients needing PC would like to receive them at home, which constitutes an increase in well-being.

HENKO means in Japanese a profound and transformative change. Thus, this project seeks to establish a community of knowledge to strengthen CP systems and lead to organizational change. HENKO NET aims to promote innovation and the adoption of innovative digital technologies so that continuous care is possible at patients’ homes and in rural areas.

The partners in this project will seek a joint strategy to promote innovative advanced training and exchange of best practices in new care models and the adoption of effective digital technologies among healthcare professionals.

The most innovative result expected from this project will be the development of the HENKO platform based on artificial intelligence for the early detection of the need for CP and the anticipation of unwanted events (medical or social). This is expected to significantly improve the organization of care with more effective monitoring at home and a reduction in hospitalizations.

Patients, families and professionals will be actively involved in this development and will be piloted with 100 patients to determine its effectiveness and efficiency. Cooperation between beneficiaries from the three countries (SP, FR and PT) is essential, since innovation in this area is very scarce, so expanding the work scenario at a transnational level will provide sufficient knowledge to develop solutions.

Selected publications (up to five)
  • Almeida, S. N., Elliott, R., Silva, E. R., & Sales, C. M. D. (2019). Fear of cancer recurrence: A qualitative systematic review and meta-synthesis of patients’ experiences. Clinical psychology review, 68, 13–24. https://doi.org/10.1016/j.cpr.2018.12.001
  • Moreira, I., Ferreira, M., Garcia, S., Novais, P., Gama, J., Ferro, B., Leite-Silva, P., Frutuoso, C., Pires, M., Barbosa, A., Pinto, C., Teixeira, M. R., Pereira, D., & Bartosch, C. (2023). Practical lessons learned from real-world implementation of the molecular classification for endometrial carcinoma. Gynecologic oncology, 176, 53–61. https://doi.org/10.1016/j.ygyno.2023.07.005
  • Mazza, M., Piperis, M., Aasaithambi, S., Chauhan, J., Sagkriotis, A., & Vieira, C. (2022). Social Media Listening to Understand the Lived Experience of Individuals in Europe With Metastatic Breast Cancer: A Systematic Search and Content Analysis Study. Frontiers in oncology, 12, 863641. https://doi.org/10.3389/fonc.2022.863641
  • Henriques-Abreu, M., & Serrano, C. (2021). Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy. Expert review of anticancer therapy, 21(10), 1081–1088. https://doi.org/10.1080/14737140.2021.1963235

Precancerous Lesions & Early Cancer Management Group

The PRECAM group represents a unique network in the field of clinical and translational research in Early Cancer, with a greater focus on Gastrointestinal Oncology, bringing together researchers from different leading cancer institutions, such as the IPO of Porto, IPO of Coimbra and the University Hospital Centre of Porto.

This multidisciplinary team focuses on the main mission of creating new knowledge and evaluating new and disruptive technologies in a comprehensive and integrative vision, to improve the diagnosis and follow-up of patients with precursor lesions and early cancer, through the personalization of healthcare. It is also our priority to understand groups’ perceptions on cancer screening/management to guide the development of effective healthcare strategies that better meet the needs of both citizens/patients and providers.

SCIENTIFIC COORDINATOR

Mário Dinis Ribeiro, MD, PhD
ORCID ID/Ciência ID: 0000-0003-0121-6850 / 731E-7010-177F
Senior Consultant Gastroenterologist
Director of the Medicine Department IPO Porto
Sub-coordinator TL2 – Cancer, RISE-Associated Laboratory
Invited Full Professor MEDCIDS / FMUP
Email: mario.ribeiro@ipoporto.min-saude.pt

TEAM
Senior Researcher

Ana Carina Pereira, PhD
ORCID ID/Ciência ID: 0000-0003-4302-2501 / 3515-2BE2-B60D
Assistant Researcher (2023.14811.TENURE.002)
Email: ana.martins.pereira@ipoporto.min-saude.pt

Junior Researchers

Catarina Lopes, PhD
ORCID/Ciência ID: 0000-0003-0176-286X / 6719-02C2-856E
Research Technician (AIDA|ID: 101095359)
E-mail: catarina.p.lopes@ipoporto.min-saude.pt

Patrícia Alves, PhD
ORCID ID/Ciência ID: 0000-0002-2105-6367/ E11A-503D-5267
Junior Researcher (EUCanScreen | ID 101162959)
E-mail: patricia.alves@ipoporto.min-saude.pt

Other Researchers

Ana Paula Santos, MD, PhD
ORCID ID/Ciência ID: 0000-0002-8896-305X / BC1E-DE39-17DF
Consultant, Endocrinology
E-mail: anapaulasantos@ipoporto.min-saude.pt

Diogo Libânio, PhD
ORCID ID/Ciência ID: 0000-0003-2691-7522 / 1C13-7D9E-A4B5
Consultant, Gastroenterology
E-mail: diogo.monteiro@ipoporto.min-saude.pt

Associated Researchers

Andreia Albuquerque, MD, PhD
ORCID ID/Ciência ID: 0000-0001-5258-2987 / DD1A-51B5-316E
Consultant, Gastroenterology UFP/Associate Professor UA
E-mail: a.albuquerque.dias@gmail.com

Filipa Fontes, PhD
ORCID ID/Ciência ID: 0000-0001-9246-589X / 5F10-FB9E-C805
Clinical Operations Specialist, Bial
Email: filipafmf@gmail.com

Miguel Areia, MD, PhD
ORCID ID/Ciência ID: 0000-0001-9787-8175 / 3516-7AAD-D948
Consultant, Gastroenterology IPO Coimbra
E-mail: miguel.areia75@gmail.com

Pedro Pimentel Nunes, MD, PhD
ORCID ID/Ciência ID: 0000-0002-7308-3295 / 0616-5C59-DC3B
Consultant, Gastroenterology Unilabs & Assistant Professor FMUP
E-mail: pedronunesml@gmail.com

Ricardo Marcos Pinto, MD, PhD
ORCID ID/Ciência ID: 0000-0001-9695-8261 / 791D-EF1B-B4C7
Consultant, Gastroenterology CHUSA & Assistant Professor ICBAS
E-mail: ricardomarcospinto@sapo.pt

Ricardo Kuttner-Magalhães, MD, PhD
ORCID ID/Ciência ID: 0000-0002-8522-5756 / F31A-B091-3D92
Gastroenterologist & Invited Professor ICBAS
E-mail: rkuttner@gmail.com

PhD Students

With External Funding

Supervision

Adriana Valentim Serra, MSc
ORCID/Ciência ID: 0009-0005-4616-5462/ B711-456D-B60C
E-mail: adriana.serra@ipoporto.min-saude.pt

Tatiana Almeida, MSc (FCT 2024.00816.BD, in collaboration with Cancer Genetics Group – CGG)
ORCID/Ciência ID: 0000-0002-9444-8257 /CD18-88C4-CE90
E-mail: tatiana.almeida@ipoporto.min-saude.pt

Co-Supervision

Daniela Rocha Santos, MSc (FCT UI/BD/154820/2023  in collaboration with Experimental Pathology & Therapeutics Group – EPTG & Clinical Research Unit – CRU)
ORCID/ CIÊNCIA ID: 0000-0003-1081-5142/ 4617-DBEA-8AE6
E-mail: daniela.r.santos@ipoporto.min-saude.pt

Mariana Gonçalves Eiras, MSc (FCT 2024.04511.BD, in collaboration with Experimental Pathology & Therapeutics Group – EPTG & with Cancer Genetics Group – CGG)
ORCID/ CIÊNCIA ID: 0009-0006-7483-4771/ F310-BAED-C2E9
E-mail: mariana.eiras@ipoporto.min-saude.pt

Renato Carvalho, MSc (GPTE) (FCT 2025.02935.BDANA,  in collaboration with Experimental Pathology & Therapeutics Group – EPTG)
ORCID/ CIÊNCIA ID: 0009-0009-5272-4178/ 4817-5B7F-4D35
E-mail: renato.carvalho@ipoporto.min-saude.pt

Research Assistant/Technicians

Anastasiia Udovyka, MSc
ORCID/Ciência ID: 651D-3EC8-A038/ 0009-0001-5662-6251
Research Assistant (Gate 15198-COMPETE2030-FEDER-00886200)
E-mail: anastasiia.udovyka@ipoporto.min-saude.pt

Raquel Ramos, MSc 
ORCID/Ciência ID: 0000-0002-3691-9196/ EE12-F786-0962
Research Technician (TOGAS|ID: 101101252)
E-mail: raquel.a.ramos@ipoporto.min-saude.pt

MSc Students

2026/2027

Supervisão

Leonor Carvalho, BSc, Master in Medicine and Molecular Oncology, FMUP

2025/2026

Rúben Marques da Costa Alves, BSc; Master in Educational Sciences, FPCEUP

Outros colaboradores

Catarina Brandão, MD; Head of the Gastroenterology Department
Inês Marques de Sá, MD; Attending Gastroenterologist
Raquel Ortigão, MD; Attending Gastroenterologist

Objetivos

Committed to advancing diagnosis and monitoring of precursor lesions and early-stage cancer through personalized healthcare, the PRECAM group will focus on:
– Assessing the feasibility and effectiveness of screening programs in digestive cancers in Portugal and Europe.
– Developing non-invasive, accessible and scalable diagnostic tests, like liquid biopsies.
– Enhancing minimally invasive diagnostic techniques, such as endoscopy, with improved quality and leveraging AI.
– Improving clinical management by creating decision-making tools, intervention strategies, and conducting cost-effectiveness studies to enhance patient outcomes and healthcare efficiency.
– Understanding citizens’, patients’ and healthcare providers’ perceptions towards screening and management of precancerous lesions in gastrointestinal tract, including their preferences, knowledge and intention to adhere, and contributing to the promotion of cancer screening adherence.
– Developing capacity and fostering sustainable change in gastrointestinal cancer screening and early diagnosis by contributing to the advancement of lifelong medical education.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)

 

Selected publications

Antonelli G, et al. QUAIDE – Quality assessment of AI preclinical studies in diagnostic endoscopy. Gut 2024;74(1):153-161

Rei A, et al. Metachronous lesions after gastric endoscopic submucosal dissection: First assessment of the FAMISH predicting score. Endoscopy. 2023 May 9. doi: 10.1055/a-2089-6849

Libânio D, et al. Prospective comparative study of endoscopic submucosal dissection and gastrectomy for early neoplastic lesions including patients’ perspectives. Endoscopy 2019;51(1):30-39. doi.org/10.1055/a-0628-6601

Areia M, et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018;6(2):192-202. doi.org/10.1177/2050640617722902

Hess T, et al. Dissecting the genetic heterogeneity of gastric cancer. EBioMedicine. 2023;18(92):104616. doi: 10.1016/j.ebiom.2023.104616

NATIONAL COLLABORATIONS

Adelino Leite-Moreira | UnIC
Conceição Calhau | CINTESIS / UNL
Diogo Caetano & Elisabete Fernandes | INESC MN & INL
Miguel Coimbra | INESC TEC
Salomé Pinho | i3s

INTERNATIONAL COLLABORATIONS / CONSORTIUM

Anax Fotopoulos / Markus Mohler |ONCOSCREEN Consortium, Greece
Javier P. Gisbert / Francis Megraud / Colm O’Morain / Adrian G. McNicholl | Hp-EuReg – European Registry on the Management of Helicobacter Pylori Infection, Spain
Johannes Schumacher | Centre for Human Genetics, University of Marburg, Germany
Marcis Leja / Tamara-Matysiak-Budnik / Iris Vogelaar-Lansdorp / Zorana Maravic / Javier P. Gisbert / Juozas Kupcinskas / Dan Lucian Dumitrascu / Annemieke Smet / Mike Morrissey / Katarzyna Neubauer / Nadan Rustemovic / Sandra Milic / Wessel vaonn de Veerdonk / Victoria McEneaney / Jochen Weigt |TOGAS Consortium, Latvia
Marino Venerito / Peter Malfertheiner | staR – European Network on the Germline Genetics of Gastric Cancer, Germany
Michael Mwachiro / Florian Lordick / Amos Mwasamwaja / Lars Aabakken | Afroc – Africa Connect Project: African Initiative against Oesophageal Cancer, Kenya and Botswana-Ethiopia-Rwanda-South Africa-Tanzania-Uganda Germany and Czech Republic-Netherlands-Portugal-Sweden-USA
Rodrigo Jover | European Polyp Surveillance (EPoS) Trials, Europe
Talía Malagón / Kimon Chatzistamatiou / Elisabeth McClymont / Staci Sudenga / Anna R Giuliano | IPVS Early Career Working Group,Switzerland
Tania Fleitas / Marcis Leja / Fátima Carneiro / Javier P. Gisbert / Leticia Moreira / Tamara Matysiak-Budnik / Laimas Jonaitis / Mário Dinis-Ribeiro / Manon Spaander | AIDA Consortium, Spain

*The information described in the group is the sole responsibility of the respective coordinator.

Epidemiology, Outcomes, Economics & Management in Oncology Group

GEREGO research activity encompasses research at population level (RORENO and RON) and hospital level and in several areas of knowledge, meeting the level of challenges that health systems face globally and assuming that the management of health care health should have a strong component of clinical results (Value-Based Health Care). Thus, the group has contributed to increase the knowledge about the epidemiology of cancer, including geographic distribution of incidence, influence of socioeconomic determinants, assessment of the impact of the disease on the population by quantifying the global burden of disease. In addition, the group has produced knowledge in the areas of management, health outcomes and health care economics.

SCIENTIFIC COORDINATOR

Maria José Bento, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-7690-9830 / 2A1A-1FCE-F83E
Senior Consultant in Public Health
Head of Department of Epidemiology
Coordinator of the Portuguese National Cancer Registry
Guest Associate Professor, ICBAS-School of Medicine & Biomedical Sciences, University of Porto
Email: mjbento@ipoporto.min-saude.pt

TEAM
Junior Researchers

Luísa Lopes-Conceição, PhD
ORCID ID/ Ciência ID: 0000-0002-5064-9911 / B912-6BD5-D2C8
Junior Researcher (ONCOVALUE| ID: 101095245)
E-mail: luisa.conceicao@ipoporto.min-saude.pt

Other Researchers

Ana Filipa Gonçalves, PhD
ORCID ID/ Ciência ID: 0000-0003-4962-3260 / 4E1E-3BC4-6DA3
Data manager
Email: ana.goncalves@ipoporto.min-saude.pt

Ofélia Godinho, PhD
ORCID ID / Ciência ID: 0000-0003-3726-4264 / 431A-ACA6-1CBE
Statistician/Bioinformatician
E-mail: ofelia.godinho@ipoporto.min-saude.pt

Rita Silva, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-1422-0974 / A41B-F09C-4DA2
Clinical Hematologist
E-mail: rita.silva@ipoporto.min-saude.pt

PhD Students with External Funding

Supervision

Mariana Pinto de Sousa, MSc (in collaboration with Experimental Pathology & Therapeutics Group – EPTG) (FCT UI/BD/154828/2023)
ORCID ID/ Ciência ID: 0000-0001-5232-2384 / 151A-5FC2-8034
E-mail: mariana.p.sousa@ipoporto.min-saude.pt

Co-Supervision

Débora Abreu, MSc (2023.05410.BDANA, in collaboration with FPCEUP)
ORCID ID/ Ciência ID: 0000-0002-0531-4047 / A113-1238-5DF2
E-mail: up201304244@edu.fpce.up.pt

PhD Students #IPO Porto Staff

Co-Supervision

Ana Catarina Alves Rodrigues, MD, MSc (in collaboration with Experimental Pathology & Therapeutics Group – EPTG)
ORCID ID / Ciência ID: 0009-0004-3034-4530 / 8018-881D-7BDE
E-mail: ana.a.rodrigues@ipoporto.min-saude.pt

Susana Pinto, PharmD (FCT Doutor AP 2024.13883.DAP, in collaboration with UCIBIO)
ORCID ID/ Ciência ID: 0009-0008-8364-6558 / DB10-0809-90D1
E-mail: susana.pinto@ipoporto.min-saude.pt

Research Assistants/Technicians

Ana Cláudia Ferreira, MSc (Gilead_ROAD-DLBCL)
ORCID ID / Ciência ID: 0000-0002-7434-3386 / 6712-D68D-F360
Data manager
E-mail: claudia.coelho.ferreira@ipoporto.min-saude.pt

Diana Alves, MSc (E-OEN-2025)
ORCID ID / Ciência ID: 0009-0005-7616-5172 / 4219-EC78-AC8C
Data manager
E-mail: diana.l.alves@ipoporto.min-saude.pt

Flávia Castro; MSc (E-OEN-2024)
ORCID ID / Ciência ID: 0000-0002-9462-2104 / DE12-0D6A-06DD
Data manager
E-mail: flavia.castro@ipoporto.min-saude.pt

Rui Pedro Pereira, MSc (E-OEN-2025)
ORCID ID / Ciência ID: 0009-0009-4191-9797 / 3218-FC13-315D
Data manager
E-mail: rui.r.pereira@ipoporto.min-saude.pt

Sílvia Torres, MSc (E-OEN-2024)
ORCID ID / Ciência ID: 0009-0002-8865-529X/ 981A-65C0-F41A
Data Manager
E-mail: silvia.torres@ipoporto.min-saude.pt

MSc Students

2026/2027

Supervision

Claúdia Ferreira Pinho, BSc, Master in Biostatistics and Bioinformatics Applied to Health – E2S-UTP

Other collaborators:

Álvaro José Silva, MD, MSc, Physician in Palliative Care
Ana Margarida Cabral, MD,MSc; Surgeon (Horta Hospital)
Ana Sofia Oliveira, BSc Management Technician
Cláudia Teixeira; MSc, Statiscian / Data analyst
Henriqueta Sampaio; BSc, Oncology Pharmacist
Joana Gomes, MSc, Oncology pharmacists
Joana Moreira, MSc, Statistician (IQVIA)
Mariana Cantante Ferreira, MSc, Data Manager
Marta Moreira, BSc, Technical Assistant
Marta Rangel, BSc, Management Technician
Pedro Leite-Silva, MSc,Statistician
Rita Calisto, MSc, Data analyst
Teresa Mota Garcia, MD MSc, Physician in Public Health
Virgínia Sousa, MSc, Management Technician

AIMS

The group intends to have a local and global impact on health care by incorporating a multidisciplinary perspective in the production of knowledge in the following areas:
– Cancer epidemiology, including cancer etiology and socioeconomic determinants;
– Clinical epidemiological research into predictive and prognostic factors of patient survival;
– Health care management, outcome research and health economics.
GEREGO research in these areas can be leveraged by strong integration with clinical practice.

In the future, the group aims to increase national and international partnerships in projects, support observational studies and publish and communicate.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)

 

SELECTED PUBLICATIONS (up to five):
Brito-Rocha T, Constâncio V, Leite-Silva P, Carvalho-Maia C, Sequeira JP, Salta S, Lobo J, Machado DI, Nunes SP, Silva-Santos R, Freitas R, Gonçalves Dias C, Vieira C, Soares M, Henrique R, Jerónimo C. Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test. Int J Cancer. 2025 Sep 1;157(5):1006-1019. doi: 10.1002/ijc.35467. Epub 2025 May 2. PMID: 40317486.

Gonçalves E, Fontes F, Rodrigues JR, Calisto R, Bento MJ, Lunet N, Morais S. The contribution of second primary cancers to the mortality of patients with a first primary breast cancer. Breast Cancer Res Treat. 2024 Sep;207(2):323-330. doi: 10.1007/s10549-024-07361-3. Epub 2024 Jun 13. PMID: 38869665; PMCID: PMC11297125.

Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, Snider JT, Neelapu SS, Ribeiro MT, Brookhart MA, Ghesquieres H, Radford J, Gribben JG. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022 Aug 25;140(8):851-860. doi: 10.1182/blood.2021014375. PMID: 35679476; PMCID: PMC9412012.

Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, Van Damme N, Valerianova Z, Atanasov T, Májek O, Mužík J, Nilbert MC, Tybjerg AJ, Innos K, Mägi M, Malila N, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Katalinic A, Walsh PM, Senore C, Rosso S, Vincerževskienė I, Lemmens VEPP, Elferink MAG, Johannesen TB, Kørner H, Pfeffer F, Bento MJ, Rodrigues J, Alves da Costa F, Miranda A, Zadnik V, Žagar T, Lopez de Munain Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Chirlaque MD, Ballesta M, Sundquist K, Sundquist J, Weber M, Jordan A, Herrmann C, Mousavi M, Ryzhov A, Hoffmeister M, Brenner H. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021 Jul;22(7):1002-1013. doi: 10.1016/S1470-2045(21)00199-6. Epub 2021 May 25. PMID: 34048685.

Libânio D, Rodrigues JR, Bento MJ, Ebigbo A, Messman H, Verhoeven RHA, Van Damme N, Bisschops R, Spaander MCW, Dinis-Ribeiro M. Gastric cancer incidence and mortality trends 2007-2016 in three European countries. Endoscopy. 2022 Jul;54(7):644-652. doi: 10.1055/a-1673-1118. Epub 2021 Dec 16. PMID: 34666399.

NATIONAL COLLABORATIONS:

Registo Oncológico Nacional de Todos os Tumores na População Residente em Portugal, em 2019
Institution: National Cancer Registry (Portugal)
Description: The publication of the National Cancer Registry (RON) aims to disseminate information regarding the incidence and mortality of cancer in Portugal in 2019. The data presented refer to all tumors in the population residing in Portugal at the time of diagnosis, excluding cases handled under cooperation protocols, for example, with Portuguese-speaking African Countries. The publication comprises incidence and mortality data, incidence distribution maps of the main types of tumor and the assessment of the quality of information, through the mortality/incidence ratio and comparison with the national incidence of 2010 and 2018.

INTERNATIONAL COLLABORATIONS:

E-OEN – European Oncology Evidence Network
Description: The Oncology Evidence Network is a research network of Europe’s larger cancer hospitals working with IQVIA to provide high quality, real world data reflecting the latest clinical practice. E-OEN is set up to simplify delivery of up-to-date real-world evidence.

Link: https://www.iqvia.com/solutions/real-world-evidence/evidence-networks/oncology-evidence-network

VENUSCANCER – Women’s cancers: do variations in patterns of care explain the world-wide inequalities in survival and avoidable premature deaths?
Description: The EU-funded VENUSCANCER project is seeking to understand the reasons behind starkly different patterns of survival and avoidable deaths in cancers affecting women around the world. This project will show that it is possible (a) to collect high-quality, complete clinical information at population level even in low- and middle-income countries; (b) to explain the striking inequalities in women’s cancer survival world-wide, and (c) to summarize these inequalities in a single number (avoidable deaths) as a powerful tool that motivates policymakers to reduce inequalities in survival.

Link: https://cordis.europa.eu/project/id/772345

PancreOS – Pancreatic cancer overall survival registry in Europe
Description: The PancreOS is aimed to be a European network of pancreatic cancer registries to improve the collection of a comprehensive set of prospective data from pancreatic cancer patients at any stage of the disease, so to fill the gap of the lack of organized data collection in pancreatic cancer and to promote a better understanding of the disease and the development of more efficacious diagnosis strategies and personalized treatments. Among the specific objectives: to implement a European network of pancreatic cancer registries to provide a comprehensive view of pancreatic cancer patient management in Europe; to identify and present the inequalities in reporting pancreatic cancer data; to promote a better understanding of the disease and the development of more effective diagnosis strategies and personalized treatments.

Link: https://pancreaticcancereurope.eu/project/pancreos-pancreatic-cancer-overall-survival-registry-in-europe-2021/

VOICE – Value based healthcare for Outcomes In breast and lung Cancer in Europe
Description: The project is based on the Value-Based Healthcare (VBHC) model that proposes an innovative strategic framework aimed at guiding healthcare services in their re-organization to provide patients with the highest value healthcare at the best cost, specifically in the case of breast and lung cancer.

Link: https://www.kronikgune.org/en/european-community-voice/
https://www.kronikgune.org/en/the-voice-community-nominated-for-the-value-based-dragons-grant-endorsement-2021-awards/

DigiCore – DiGital Institute for Cancer Outcomes Research
Description: DIGICORE is a pan-European research network built to accelerate the Implementation of precision oncology in Europe. DIGICORE promotes and equips cancer centers in their use of routine electronic health records (EHR) and molecular diagnostic information (MDX) for trial automation, real world outcomes research, digital diagnostics and care quality management. The goal is to shape a digital research infrastructure based on digital interoperability between its Members. Network membership supports them to improve data quality and completeness, develop new data sources and tools, share digital best practices and promote novel, digitally enabled research methods.

Link: https://digicore-cancer.eu/

OECI Working Group on Cancer Economics and Benchmarking
Description: The primary objectives of the WG is to demonstrate remits of cost-benefits analyses in oncology and to establish standards in budget impact analysis for OECI members.

Link: https://www.oeci.eu/WG.aspx?id=12&group=1

IPAAC – Innovative Partnership for Action Against Cancer WP7 PILOT 2
Institution: Italian National Institute of Health, Italy
Description: The IPAAC Joint Action brings together 24 Associated Partners (with Affiliated Entities, 44 partners) across Europe whose main objectives are to build upon deliverables of the CANCON Joint Action and to implement innovative approaches to cancer control. A Roadmap on Implementation and Sustainability of Cancer Control Actions will be the main deliverable of this Joint Action.

Link: https://www.ipaac.eu/

CONCORD – Global surveillance of cancer survival
Institution: London School of Hygiene & Tropical Medicine, UK
Description: CONCORD is the program for world-wide surveillance of trends in cancer survival, led by the London School of Hygiene & Tropical Medicine. The CONCORD program is endorsed by 40 national and international agencies, including WHO EURO, the Organization for Economic Co-operation & Development (OECD) and the World Bank.

Link: https://csg.lshtm.ac.uk/research/themes/concord-programme

WASABY – WAter & Soil contamination and Awareness on Breast cancer risk in Young women
Institution: Istituto Nazionale Tumori di Milano, Italy
Description: The proposal involves the design of a model able to identify areas with higher cancer rates, so to study whether pollutant contamination may be a cause for increased cancer risk. Hence it aims to improve the health of EU citizens and reduce health inequalities.

Link: http://www.wasabysite.it/

EUROCARE – Survival of cancer patients in Europe
Institution: Istituto Nazionale Tumori di Milano and of the Italian National Institute of Health, Italy
Description: EUROCARE is the widest collaborative research project on cancer survival in Europe. The project started in 1989 under the initiative of two research institutes, Istituto Nazionale Tumori (Milan, Italy) www.istitutotumori.mi.it and Istituto Superiore di Sanità (Rome, Italy) www.iss.it, with the participation of many population-based Cancer Registries throughout Europe. Aims of the study are: to provide an updated description of cancer survival time trends and differences across European countries, to measure cancer prevalence, and to study patterns of care of cancer patients.

Link: http://www.eurocare.it/

RARECAREnet – Surveillance of Rare Cancers in Europe
Institution: Istituto Nazionale Tumori di Milano, Italy
Description: Building on the experience of the previous project RARECARE and, in collaboration with RCE and many other RARECARENet aims at building an information network to provide comprehensive information on rare cancers to the community at large (oncologists, general practitioners, researchers, health authorities, patients and their families).

Link: https://www.rarecarenet.eu/

IICC – International Incidence of Childhood Cancer
Institution: International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR), France
Description: The objective is to disseminate the available data on the incidence of cancer in children around the world. This will be achieved through the publication of a monograph, the third volume in the IICC series (IICC-3). Data from 440 registries in five continents have been collected, validated, analyzed, and evaluated.

Link: https://iicc.iarc.fr/

EURECCA – EUropean REgistry of Cancer CAre or EURopEan CanCer Audit
Institution: ESSO (European Society of Surgical Oncology), Belgium
Description: EURECCA is an international multidisciplinary platform of clinicians and epidemiologists aiming to improve the quality of cancer care by data registration, feedback, forming plans for improvement and sharing knowledge of performance and science. EURECCA’s goal is to enlarge the European platform and infrastructure to cooperate with national registries or audit structures, expand the coverage of cancer patient outcome data that is captured and audit the quality of multidisciplinary cancer care.

Link: https://www.essoweb.org/projects/eurecca-cancer-care/

EurocanPlatform for Translational Cancer Research
Institution: Karolinska Institutet, Sweden
Description: EurocanPlatform will work towards the goal of decreasing cancer mortality by dealing with three main areas of strategic research: prevention, early detection and improved treatments. It will build the necessary resources and know-how for the entire research continuum: basic research, early and late translational research, clinical research, epidemiological research, implementation in care and population based outcome research.

Link: https://eurocanplatform.eu/category/industries/

UNCAN.eu, a European initiative to UNderstand CANcer
Instituição: Institut National de la Santé et de la Recherche Médicale, France
Description: The blueprint for UNCAN.eu will propose to set up a European Federated Cancer Research data hub and to generate a series of use cases, addressing major challenges in cancer research. These ambitious and innovative, but realistic and focussed, use cases will be cross-border and trans-disciplinary research programmes built in a problem-solving manner. Results of these use cases will feed the Cancer Research data hub with findable, accessible, interoperable, and re-usable (FAIR) cancer research data. These research data will be combined with patient health and any other relevant data (e.g., from longitudinal cohorts, geographical observations, consumer and lifestyle data) at an unprecedented scale. UNCAN.eu that will bring all relevant players and information together, based on existing efforts in Europe and beyond.

Link: https://uncan.eu/

GRELL – Group for Cancer Epidemiology and Registration in Latin Language Countries

Link: https://www.grell-network.org/

CRICCS – Cancer Risk in Childhood Cancer Survivors: understanding the causes to target prevention

Link: https://criccs.iarc.who.int /

 

*The information described in the group is the sole responsibility of the respective coordinator.

CANCER BIOLOGY & EPIGENETICS GROUP

The team integrates predoctoral and postdoctoral researchers, with diverse academic backgrounds, including Biologists, Biochemists, Pharmacists, Pathological Anatomy graduates, and Medical Doctors of several specialties, including Pathologists, Urologists, Gynecologists, Radiologists, Haemato-Oncologists, and Medical Oncologists.

In the context of Precision Oncology, we are developing several patient-centered pre-clinical and fundamental research projects addressing tumor biology, pathology, epigenetics, epitranscriptomics, tumor metabolism, and immunology topics.

SCIENTIFIC COORDINATOR

Carmen Jerónimo, PhD
ORCID ID/ Ciência ID: 0000-0003-4186-5345/ CE16-29CB-EDD1
Assistant Researcher
IPO Porto Research Director
Scientific Coordinator, Biobank – Department of Pathology
TL2 – Cancer Coordinator, RISE-Associate Laboratory
Guest Full Professor, ICBAS-School of Medicine & Biomedical Sciences, University of Porto
Chair, Translational Research Section/ESUR of the European Association of Urology
E-mail: carmenjeronimo@ipoporto.min-saude.pt/cljeronimo@icbas.up.pt

TEAM
Senior Researchers

Rui Henrique, MD, PhD
ORCID ID/ Ciência ID: 0000-0003-3171-4666 / 641F-FE09-15E6
Senior Researcher
Senior Consultant Pathologist and Director, Department of Pathology
Guest Full Professor, ICBAS-School of Medicine & Biomedical Sciences, University of Porto
E-mail: henrique@ipoporto.min-saude.pt/ rmhenrique@icbas.up.pt

Margareta P. Correia, PhD
Assistant Researcher (2023.14811.TENURE.001)
Team Leader of the research topic: Onco-Immuno-Epigenetics
Lecturer at ICBAS-UP under the IPO Porto & ICBAS-UP Protocol
E-mail: margareta.correia@ipoporto.min-saude.pt

Junior Researchers

João Lobo, MD, PhD
Consultant Pathologist, Department of Pathology
ORCID ID/ Ciência ID: 0000-0001-6829-1391/ 8A14-8221-1CBF
Team Leader of the research topic: Testicular Tumors
Guest Assistant Professor, ICBAS-UP
E-mail: jpedro.lobo@ipoporto.min-saude.pt

Sara Monteiro-Reis, PhD
ORCID ID/ Ciência ID: 0000-0002-2193-2793/ 3014-05F4-935F
Project Manager (EUnetCCC JA | ID: 101183407)
Lecturer at ICBAS-UP under the IPO Porto & ICBAS-UP Protocol
E-mail: sara.reis@ipoporto.min-saude.pt

Vera Miranda-Gonçalves, PhD
ORCID ID/ Ciência ID: 0000-0002-4231-5532/ 8E1B-B722-284F
LAB3 Manager (UID/00776/2025 | https://doi.org/10.54499/UID/00776/2025)
Lecturer at ICBAS-UP under the IPO Porto & ICBAS-UP Protocol
E-mail: vera.miranda.goncalves@ipoporto.min-saude.pt

Other Researchers

Carla Bartosch, MD, PhD
ORCID ID/ Ciência ID: 0000-0003-0646-7667/ 881F-BDAC-46FE
Consultant Pathologist, Department of Pathology
Guest Associate Professor at School of Life and Environmental Sciences, University of Trás-os-Montes and Alto Douro
E-mail: carla.bartosch@ipoporto.min-saude.pt

Liliana Raimundo, PhD
ORCID ID/ Ciência ID: 0000-0001-9003-2601 / B21B-623F-AA05
Molecular Pathology Technician
E-mail: liliana.raimundo@ipoporto.min-saude.pt

Sérgio Lopes, PhD
ORCID ID/ Ciência ID: 00000-0002-4002-1071 / A614-5E1D-A6D7
Cell Therapy Clinical Scientist
E-mail: sergio.lopes@ipoporto.min-saude.pt

Sofia Salta, PhD
ORCID ID/ Ciência ID: 0000-0002-6707-1263 / 6119-2B18-6A26;
Scientific Manager (UID/00776/2025 | https://doi.org/10.54499/UID/00776/2025)
E-mail: sofia.salta@ipoporto.min-saude.pt

Associated Researchers

Diana Montezuma, PhD
Pathologist and Head of R&D Unit at IMP
ORCID ID/ Ciência ID: 0000-0001-9551-4589 / 8614-D72D-4861
E-mail: diana.m.felizardo@ipoporto.min-saude.pt

Afillated Researchers

Óscar Rapado González, DDS, PhD
Postdoctoral Researcher – Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
ORCID ID/ Ciência ID: 0000-0001-8419-7004 / C019-EAAE-BBB8
E-mail: oscar.gonzalez@ipoporto.min-saude.pt

Vera Constâncio, PhD
La Caixa Health Innovation Fellow, Spain
ORCID ID/ Ciência ID: 0000-0002-3151-0367/ 3116-280A-8462;
E-mail: vera.salvado.constancio@ipoporto.min-saude.pt

PhD Students

With External Funding

Supervision

Alice Manuela Santos Alves, MD
ORCID ID/ Ciência ID: 0009-0001-9144-4912/ B118-A5D4-72E3
E-mail: alicemalves@gmail.com

Amal Magdy Mohamed, MSc (in collaboration with KU Leuven, Belgium; HORIZON-MSCA-2022-DN-01, GA 101120283 – PROSTAMET)
ORCID ID/ Ciência ID: 0009-0004-0514-9725 / BB1D-00E9-DB8C
E-mail: aml.mohamed@ipoporto.min-saude.pt

Ana Beatriz Oliveira, MD
ORCID ID/ CIÊNCIA ID 0000-0002-6062-0688/FC16-A045-766F
E-mail:ana.b.s.oliveira@ipoporto.min-saude.pt

Ana Teixeira-Marques, MSc (in collaboration with i3S/ Centro de Investigación Hospital Universitario 12 de Octubre, Espanha; FCT2023.01232.BD);
ORCID ID/Ciência ID: 0000-0003-1396-3466/ 601F-802B-922D;
E-mail: ana.t.marques@ipoporto.min-saude.pt

Beatriz Loureiro, MSc
ORCID ID/ Ciência ID: 0009-0008-4298-1544 /4A17-2360-CB93
E-mail: beatriz.loureiro@ipoporto.min-saude.pt

Fernanda Fernandes-Pontes, MSc (in collaboration with ICVS; FCT 2025.02046.BD)
ORCID ID/ Ciência ID: 0009-0007-3931-0443 / 1C19-894E-FD30
E-mail: fernanda.pontes@ipoporto.min-saude.pt

Filipa Domingues dos Reis, MSc (in collaboration with Leiden University Medical Centre, The Netherlands; FCT UI/BD/154816/2023);
ORCID ID/ Ciência ID: 0000-0001-9897-5612/ C014-A6CE-0341;
E-mail: filipa.reis@ipoporto.min-saude.pt

Filipa Moreira Silva, MSc (in collaboration with Bern University Hospital, Bern, Switzerland; FCT 2023.00300.BD);
ORCID ID/ Ciência ID: 0000-0002-7272-7300/ 7019-D06D-3E3F;
E-mail: filipa.m.silva@ipoporto.min-saude.pt

Íris da Rocha Carriço, MSc (in collaboration with MFRRP; FCT UI/BD/154815/2023);
ORCID ID/ Ciência ID: 0000-0002-4977-8273/ 3617-1D5C-EE2D;
E-mail: iris.carrico@ipoporto.min-saude.pt

João Martins da Gama, MD
ORCID ID/ Ciência ID: 0000-0001-5274-4114 / 9E1A-51E8-0B2C
E-mail: joao.m.gama@ipoporto.min-saude.pt; joaomartinsgama@gmail.com

João Moura e Silva, MD
ORCID ID/ Ciência ID: 0000-0001-8579-6543 / 241A-85E2-1BF3
E-mail: jricardo.moura.silva@gmail.com

José Pedro Sequeira, MSc (in collaboration IDIS, Spain; FCT2022.11060.BD);
ORCID ID/ Ciência ID: 0000-0002-4687-3347/ FE1E-E1CF-6983;
E-mail: jose.leite.sequeira@ipoporto.min-saude.pt

Mariana Lima-Costa, MSc (in collaboration with Leiden University Medical Centre, The Netherlands; FCT 2025.03036.BD)
ORCID ID/ Ciência ID: 0009-0001-3257-3693 / 261D-7564-4CD4;
E-mail: mariana.l.costa@ipoporto.min-saude.pt

Marta Avelar, MSc (in collaboration with i3S; FCT2025.02786.BD);
ORCID ID/ Ciência ID: 0000-0002-1961-6513 / 331A-DB95-F399
E-mail: marta.avelar@ipoporto.min-saude.pt

Miguel Ângelo Ferreira, MSc (in collaboration with ERASMUS MC, The Netherlands; HORIZON-MSCA-2024-DN-01, GA 101226733 – EURECA)
ORCID ID/ Ciência ID: 0009-0001-1684-5150/ 511A-9CBE-29C4
E-mail: miguel.ferreira@ipoporto.min-saude.pt

Nuno Tiago Tavares, MSc (in collaboration with the University of California, San Diego, USA; FCT2022.09566.BD);
ORCID ID/ Ciência ID: 0000-0001-8426-1838/ 2718-0ED1-9F74;
E-mail: i38161@ipoporto.min-saude.pt

 

Co-Supervision

Amna Tahir, MSc (HORIZON-MSCA-2022-DN-01, GA 101120283 – PROSTAMET, KU LEUVEN, Belgium)
ORCID ID/ Ciência ID: 0009-0009-6537-2319 / 7311-8A8E-EC5D
E-mail: amna.tahir@kuleuven.be

Ana Margarida Faria, MSc (INSA; FCT2024.02722.BDANA);
ORCID ID/ Ciência ID: 0000-0001-8890-1871/ 3210-3538-BAB8;
E-mail: ana.faria@insa.min-saude.pt; ana.maria@ipoporto.min-saude.pt

Daniele Carchidi, MSc (DBMR, UniBern, Switzerland)
ORCID ID: 0009-0005-2707-7678
E-mail: daniele.carchidi@unibe.ch

Mariana Carvalho, MSc (INEGI; FCT2022.09480.BD);
ORCID ID/ Ciência ID: 0000-0001-8620-9718/ 7713-CE2C-47D2;
E-mail: mariana.carvalho@ipoporto.min-saude.pt

Patrícia Sá, MSc (ISPUP; FCT 2025.03463.BD);
ORCID ID/ Ciência ID: 0009-0006-1868-7527/ BE13-103E-ED86;
E-mail: up202103371@edu.fcna.up.pt

PhD Students #IPO PORTO STAFF

Supervision

Ana Fernandes Rodrigues, MD;
ORCID ID/ Ciência ID: 0000-0003-2955-055 / 371A-3A6B-696F;
E-mail: ana.fernandes.rodrigues@ipoporto.min-saude.pt

Bruno Oliveira-Lopes, MSc (in collaboration with LAQV-REQUIMTE UA);
ORCID ID/Ciência ID: 0000-0001-5972-8096/ 781F-B501-A18E;
E-mail: bruno.lopes@ipoporto.min-saude.pt

Carlos Ochoa Leite, MD;
ORCID ID/ Ciência ID: 0000-0003-0489-9677 / 7B14-471C-19A5;
E-mail: carlos.ochoa.leite@ipoporto.min-saude.pt

Carina Carvalho-Maia, MSc;
ORCID ID/ Ciência ID: 0000-0002-7011-8341 / B116-C629-89AC;
E-mail: i13035@ipoporto.min-saude.pt

Isa Carneiro, MSc; Pathology Technician;
ORCID ID/ Ciência ID: 0000-0002-0561-3880 / 211C-E4FA-36A4;
E-mail: isa.carneiro@ipoporto.min-saude.pt

João André Carvalho, MD;
ORCID ID/ Ciência ID: 0000-0001-8564-2050 / B318-599E-9623;
E-mail: joao.m.carvalho@ipoporto.min-saude.pt

Lígia Gonçalves, MD;
ORCID ID/ Ciência ID: 0000-0002-5864-8526 / 0D10-301A-79F6;
E-mail: ligiagoncalves@ipoporto.min-saude.pt

Rita Guimarães, MSc, Pathology Technician;
ORCID ID/ Ciência ID: 0000-0002-1608-4494/ BA1B-8EFB-2442;
E-mail: rita.guimaraes@ipoporto.min-saude.pt

Rui Freitas, MD;
ORCID ID/ Ciência ID: 0000-0002-4448-6458/ F01F-89CB-26E6;
E-mail: antoniofreitas@ipoporto.min-saude.pt

Rui Silva-Santos, MSc; Pathology Technician;
ORCID ID/ Ciência ID: 0000-0002-6392-1785/ 0E14-7605-B96D;
E-mail: rui.silva.santos@ipoporto.min-saude.pt

Sofia Paulino, MSc; Pathology Technician;
ORCID ID/ Ciência ID: 0000-0003-1244-4066/ C31D-B4FF-D098
E-mail: sofia.paulino@ipoporto.min-saude.pt

Research Assistants/Technicians

Bárbara Amorim Fernandes, MSc (in collaboration with ISPUP, JANUS FCT 2023.17087.ICDT)
ORCID ID/ Ciência ID: 0009-0001-1229-7118/ 9616-BB80-5E6B;
E-mail: barbara.fernandes@ipoporto.min-saude.pt

Catarina Lourenço, MSc (BreastToBone COMPETE2030.FEDER-00686000|15753)
ORCID ID/ Ciência ID: 0000-0003-0644-0202/ 9A1E-2DE0-A004;
E-mail: catarina.lourenco@ipoporto.min-saude.pt

Jéssica Cordeiro, MSc (EpImmunePCa-2022.04809.PTDC)
ORCID ID/ Ciência ID: 0009-0009-9253-3632/ 9E17-72B4-AE97;
E-mail: jessica.cordeiro@ipoporto.min-saude.pt

Mariana Silva-Ferreira, MSc (HENKO_NET S1/4.5/E0091 – Interreg Sudoe);
ORCID ID/ Ciência ID: 0000-0002-5896-051X/ 521F-556D-5E8E;
E-mail: mariana.ferreira@ipoporto.min-saude.pt

MSc Students

2026/2027

Supervision

Anastasiia Ponosova, Integrated Master in Medicine, ICBAS-UP
António Karpyuk, BSc, Master in Laboratory Techniques in Biopathology, E2S-UTP
Beatriz Santos Resende, BSc; Master in Oncology, ICBAS-UP
Eduarda Pereira Alves, BSc; Master in Oncology, ICBAS-UP
Rita Vieira dos Santos, BSc; Master in Oncology, ICBAS-UP

Co-Supervision

Bárbara Miguéis, BSc, Master in Biomedicine, UM (in collaboration with ICVS)
Lara Pinto, BSc; Master in Oncology, ICBAS-UP (in collaboration with i3S

2025/2026

Supervision

Diana Almeida-Pereira, BSc; Master in Oncology, ICBAS-UP
Gonçalo Silva-Rodrigues, BSc; Master in Oncology, ICBAS-UP
Jéssica Sousa, BSc; Master in Molecular and Cellular Biology, FCUP
Mariana Melo e Costa, BSc; Master in Oncology, ICBAS-UP
Rita Botelho, BSc; Master in Legal Medicine, ICBAS-UP

Other collaborators

Alexandra Lapa, MD, Resident in Pathology
Ana Isabel Varelas, MD, Attending Pathologist
Ana Luísa Cunha, MD; Consultant Pathologist
Ana Teresa Martins, MSc; Pathology Technician
Ângelo Rodrigues, MD; Consultant Pathologist
Candy Paiva, BSc; Pathology Technician
Carla Renata Dias, MD; Consultant Pathologist
Carolina Duque, MSc; Resident in Pathology
Davide Gigliano, MD; Attending Pathologist
Fernanda Silva, BSc; Pathology Technician
Isaac Braga, MSc, Attending Urologist
João Martins, MD; Attending Medical Oncologist
Jorge Torres-Ferreira, MSc; Pathology Technician
Maria Alzamora; MD; Resident in Pathology
Mónica Pires, MD Consultant Gynecologist
Nuno Coimbra, MD; Consultant Pathologist
Paula Dias, BSc; Pathology Technician
Paula Lopes, BSc; Pathology Technician
Paula Monteiro, MD; Consultant Pathologist
Renata Vieira, BSc; Pathology Technician
Sara Cardoso, MSc; Clinical Pathology Technician
Sérgio Chacim, MD, MSc; Consultant Hematologist at USL Gaia-Espinho
Verónica Ferreira, BSc; Pathology Technician

Aims

The core aim of our group is to portray in depth epigenetic and epitranscriptomic mechanisms involved in carcinogenesis, which might be used as clinical tools for early detection, diagnosis, prognostication, and therapy prediction. The investigation of the mechanism and role of epigenetic-modulating drugs (epi-drugs) is another major goal. Moreover, owing to the relevance that Immuno-oncology has demonstrated in recent years, we are also exploring the epigenetic modulation of biomolecules involved in immune responses, aiming at the improvement of immunotherapeutic strategies.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)

 

Selected publications (up to five):

• Salta, S, Sequeira, JP, Amorim-Fernandes, B, Lobo, J, Baldaque, I, Monteiro, P, Tavares, F, Taly, V, Henrique, R and Jeronimo, C. Methylation-Specific Droplet Digital PCR: Testing a Novel Triage Tool for HrHPV-Positive Women in the Cervical Cancer Screening Program of Northern Portugal. MedComm (2020). 2025;6(7): p. e70203. IF: 10.7 doi:10.1002/mco2.70203
• Tavares, NT, Lourenco, C, Constancio, V, Fernandes-Pontes, F, Fonseca, D, Silva-Santos, R, Braga, I, Mauricio, J, Henrique, R, Liu, M, Weiss, RS, Bagrodia, A, Jeronimo, C and Lobo, J. MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors. Cell Commun Signal. 2025;23(1): p. 252. IF:8.9 doi: 10.1186/s12964-025-02250-8
• Brito-Rocha T, Constâncio V, Leite-Silva P, Carvalho-Maia C, Sequeira JP, Salta S, Lobo J, Machado DI, Nunes SP, Silva-Santos R, Freitas R, Gonçalves Dias C, Vieira C, Soares M, Henrique R, and Jerónimo C. Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test. Int J Cancer. 157(5):1006–1019, 2025. doi: 10.1002/ijc.35467.
• Albuquerque-Castro Â, Macedo-Silva C, Oliveira-Sousa R, Constâncio V, Lobo J, Carneiro I, Henrique R, and Jerónimo C. Redefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring. Biomark Res. 12(1):75, 2024. doi: 10.1186/s40364-024-00627-4.
• Macedo-Silva C, Miranda-Gonçalves V, Tavares NT, Barros-Silva D, Lencart J, Lobo J, Oliveira Â, Correia MP, Altucci L and Jerónimo C. Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling. Signal Transduct. Target. Ther. 8(1): 395, 2023. doi: 10.1038/s41392-023-01639-6.

PATENTS

(2025) A panel of eight volatile compounds as biomarkers for the early detection of bladder cancer in urine; Provisional Patent PT 20252007296028
(2025) Bladder Cancer Biomarkers, Methods and Kit; Provisional Patent PT 20252007037390
(2025) PROSTARK: Prostate cancer recurrence risk calculator; WO2025155211
(2012) Methods and biomarkers for detection of bladder cancer; US 20130210011/ EP 2630261 A1/ WO 2012052844 A1 (in collaboration Oslo University Hospital)

NATIONAL COLLABORATIONS

Celso Reis | IPATIMUP, i3S
Estrela Neto | INEB, i3S
Fátima Baltazar | ICVS/3Bs, U. Minho
Goreti Sales | U. Coimbra
Joana Paredes | IPATIMUP, i3S
João F Mano | CICECO – U. Aveiro
João P Ferreira | FEUP
Lucília Saraiva | LAQV/REQUIMTE
Luisa Helguero | IBiMED, U. Aveiro
Margarida Fardilha | IBiMED, U. Aveiro
Maria José Oliveira | INEB, i3S
Meriem Lamghari | INEB, i3S
Nuno Lunet, ISPUP
Paula Guedes | REQUIMTE-FF
Raquel Almeida | IPATIMUP, i3S
Sara Ricardo | 1H-TOXRUN, IUCS

INTERNATIONAL COLLABORATIONS

Aditya Bagrodia | University of California, San Diego, USA
Alejandro Sifrim & Johan Swinnem | KU Leuven, Belgium
Ángel Díaz-Lagares | Epigenomics Unit, Translational Medical Oncology (Oncomet), IDIS, Spain
Catherine Muller | IPBS-CNRS, Université de Toulouse, France
Elena Martens-Uzunova | Erasmus Medical Center, Rotterdam, The Netherlands
Florence Le Calvez-Kelm | IARC, Lyon, France
Gabri van der Pluijm | Leiden University Medical Center, The Netherlands
Giuseppina Carbone | Belinzona, Switzerland
Guro Lind | Radium Hospital, Oslo, Norway
Hector Peinado CNIO, Madrid, Spain
Hing Leung | CRUK-Glasgow, UK
Isabelle Bernard-Pierrot | Institut Curie, Paris, France
Jesús M. Paramio & Marta Dueñas | Biomedical Research Institute I+12, University Hospital “12 de Octubre”, Madrid, Spain
Laura Muinelo-Romay & María Mercedes Suárez-Cunqueiro | Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), IDIS, Spain
Lucia Altucci | Università degli studi della Campania “Luigi Vanvitelli”, Naples, Italy
Maija Puhka | Institute for Molecular Medicine, University of Helsinki, Finland
Manel Esteller | Josep Carreras Leukaemia Research Institute, Barcelona, Spain
Marianna Kruithof-de Julio | Bern Univ Hospital, Switzerland
Mónica Martínez-Fernández, CIMUS, University of Santiago de Compostela, Spain
Noel de Miranda| Leiden University Medical Center, The Netherlands
Paola Arimondo | Institute Pasteur, Paris, France
Sandra Blanco | Centro de Investigación del Cáncer, Salamanca, Spain
Valérie Taly | Université Paris Descartes, Paris, France
Wilbert Zwart | NKI, Amsterdam, The Netherlands

*The information described in the group is the sole responsibility of the respective coordinator.

Medical Physics, Radiobiology & Radiation Protection Group

The Medical Physics, Radiobiology & Radiation Protection Group was formed in the beginning of 2008 housed by the IPO-Porto Research Center. Its members are mainly physicists and radiobiologists but also include other expertises such as radiopharmacy and clinical practitioners. It is the only Medical Physics and Radiobiology research group in Portugal whose activities are developed entirely in a hospital environment.
The group has two Full Member (J.A.M. Santos and P.P. Teles) in the European Radiation Dosimetry Group (Eurados), and two Corresponding Member (J. Lencart and A. G. Dias), in the Workgroup 9 and 12, WG9 (Radiation Protection in Radiotherapy) and is involved in several national and international collaborations.

SCIENTIFIC COORDINATOR

João António Miranda dos Santos, PhD
João António Miranda dos Santos, PhD
ORCID ID: 0000-0003-2465-5143
CIENCIA ID: 2514-D31E-2F02
Medical Physicist, Group Leader, Member of the Ethics Committee
Email: joao.santos@ipoporto.min-saude.pt

TEAM
Senior Investigators

Anabela Gregório Dias, PhD
ORCID ID: 0000-0002-2777-321X/ CIENCIA ID: 4C12-5EAB-0C33
Medical Physicist
Email: anabela.dias@ipoporto.min-saude.pt

Isabel Maria Guedes Bravo, PhD
ORCID ID: 0000-0001-6445-6443
CIENCIA ID: 031C-23F5-F5B4
Assistant Researcher/ Radiobiologist
Email: isabel.bravo@ipoporto.min-saude.pt

Pedro Peixoto Teles, PhD
ORCID ID: 6D11-4C85-387C/ CIENCIA ID: C61C-4934-500F
Assistant Professor; FCUP/UP
E-mail: ppteles@fc.up.pt

Sofia Isabel de Castro e Silva, PhD
ORCID ID: 0000-0002-0056-6034/ CIENCIA ID: 6D11-4C85-387C
Medical Physicist, IPO Coimbra
Email: sofia.i.silva@ipocoimbra.min-saude.pt

 

Invited Researchers

Inês Campos Monteiro Sabino Domingues, PhD
ORCID ID: 0000-0002-2334-7280/ CIENCIA ID: 971F-F25B-1E79
Assistant Professor; ISEC
E-mail: inesdomingues@gmail.com

 

PhD Students

Bárbara Adélia Meireles Barbosa, MSc
ORCID ID: 0000-0003-0686-0397/ CIENCIA ID: 721A-00E6-BAC5
Radiotherapy Technologist
Email: barbara.barbosa@ipoporto.min-saude.pt

Bruno Miguel Ferreira Mendes, MSc
ORCID ID: 0000-0002-7574-7630
Email: brunomendes81@gmail.com

Sara Filipa Coelho Guerreiro, MSc
ORCID ID: 0000-0002-2334-7280/ CIENCIA ID: 971F-F25B-1E79
School of Health of the Polytechnic of Leiria
Email: sara.f.guerreiro@ipleiria.pt

 

MSc Students

Amizito Luís Rajabo
ORCID ID: 0009-0008-3439-7276/ CIENCIA ID: BF11-7036-81F9
Email: up202110020@edu.fc.up.pt

Rúben Diogo Oliveira Sousa
ORCID: 0000-0002-0776-5212/ CIÊNCIA ID: 2310-F2F9-4178
Email: ruben.d.sousa@ipoporto.min-saude.pt

 

Other Collaborators

Alexandre Baptista Mendes Pereira, BSc
ORCID ID: 0000-0001-8965-274X/ CIENCIA ID: 301D-A86A-60C0
Medical Physicist
Email: apereira@ipoporto.min-saude.pt

António Luís Soares
CIENCIA ID: A817-239C-7AC4
Medical Physicist
Email: Antonio.soares@ipoporto.min-saude.pt

Carla Isabel Vaz Tavares Figueiredo Capelo, BSc
CIENCIA ID: 9D1A-6422-C7F7
Radiopharmacist
Email: carla.capelo@ipoporto.min-saude.pt

Diana Jorge Pimparel Alves Nuno Pinto, BSc
ORCID ID: 0000-0003-2559-3407/ CIENCIA ID: D31C-57A9-559A
Medical Physicist
Email: diana.pinto@ipoporto.min-saude.pt

Filipe Augusto Madeira Dias, MSc
ORCID ID: 0000-0002-2992-5096/ CIENCIA ID: 5412-D0F2-2595
Medical Physicist
Email: filipe.dias@ipoporto.min-saude.pt

Inês Magalhães da Silva de Lucena e Sampaio, MD, MSc
ORCID ID: 0000-0003-4578-2280/ CIENCIA ID: 3918-4909-EB6E
Nuclear Medicine Physician
Email: ines.lucena@ipoporto.min-saude.pt

Joana Borges Lencart e Silva, BSc
ORCID ID: 0000-0001-7078-7257/ CIENCIA ID: 7A1A-E9DB-BECE
Medical Physics
Email: joana.lencart@ipoporto.min-saude.pt

Jorge Barbosa Pereira, MSc
ORCID ID: 0000-0002-7216-1191/ CIENCIA ID: BA13-D305-14A8
Medical Physicist
Email: jorge.b.pereira@ipoporto.min-saude.pt

Luís Hugo da Silva Trindade Duarte, MD, BSc
ORCID ID: 0000-0002-6867-1180
Nuclear Medicine Physician
Email: hugo.duarte@ipoporto.min-saude.pt

Luís Paulo Teixeira Cunha, MSc
ORCID ID: 0000-0001-6012-6893/ CIENCIA ID: 7112-7B32-F43F
Medical Physicist
Email: luis.cunha@ipoporto.min-saude.pt

Pedro Filipe Conde Andrade Silva, MSc
ORCID ID: 0000-0003-3962-4040/ CIENCIA ID: 161C-6CE9-1867
Radiology and Radiotherapy Technologist
Email: pedro.andrade.silva@ipoporto.min-saude.pt

Rita Correia da Silva Alçada Albergueiro
ORCID: 0009-0009-3211-9501/ CIÊNCIA ID: F610-FB91-C98A
Medical Physicist
Email: ritaalbergueiro@gmail.com

Rogéria Maria Craveiro Pereira, Msc
ORCID ID: 0000-0002-5786-2096/ CIENCIA ID: 0116-CFE3-35C7
Radiobiologist
Email: rogeriapereira@ipoporto.min-saude.pt

Sara Patrícia de Almeida Pinto
ORCID ID: 0000-0002-9863-2078/ CIENCIA ID: A214-DDBF-CA6E
Medical Physicist
Email: sara.pinto@ipoporto.min-saude.pt

Susana Margarida Oliveira Gonçalves
ORCID ID: 0000-0003-3036-5847/ CIENCIA ID: C119-01F8-B6F2
Dosimetrist technologist
Email: susanamg@ipoporto.min-saude.pt

Vera Catarina Marques Antunes
ORCID ID: 0000-0001-7195-8791/ CIENCIA ID: 8516-92A5-7DE5
Medical Physicist
Email: vera.antunes@ipoporto.min-saude.pt

 

AIMS 

The group focuses on the application of the methodology of physics and radiobiology to solve specific problems related to health care, especially ionizing radiation, both from the perspective of the patient procedures optimization or in the perspective of the protection in the event of professional exposure to ionizing radiation. It has already embraced critical personal exposure due to highly heterogeneous radiation fields with Monte Carlo simulations in CT-fluoroscopy and patient exposure during intra-operatory radiotherapy. This methodology, with increasing computer power over the last years, is becoming a benchmark method to simulate procedures in ionizing radiation physics, where exposure of subjects must be very well justified.

 

PROJECTS WITH INTERNAL FUNDING
  • TIPTOP – Artificial Intelligence applied to image based oncological prognosis
    PI 145-CI-IPOP-133-2020; Budget: 21.000.00€ (2019 – ongoing); PI: Prof. Inês Domingues

Artificial intelligence methods, namely Machine learning and its Deep Learning component, can be used to anticipate the prognosis and response to therapy. From the imaging modalities available in the treatment and diagnosis of a cancer patient, CT and CBCT are widely used. Radiographic findings have shown a correlation to significant differences in protein expression patterns. In this context, extracting features from radiographic images using data-characterization algorithms (Radiomics) may provide a valuable tool for cancer evaluation during treatment. The hypothesis behind radiomics is that quantitative analysis of medical images may have a similar prognosis power as phenotypes and gene protein signatures. The idea is to predict the aggressiveness of Prostate Cancer from Ct images and the effectiveness of radiation therapy from CBCT images. However, features are extracted from a region of interest previously delimited. To address this issue, several image segmentation methods will be explored for the prostate and organs at risk, such as the bladder and the rectum. Clustering, U-Net, Active Contours and Graph-Based are a few example methods that will be explored. Also, a multi-class segmentation scenario is also interesting since it mimics the holistic manual segmentation of medical experts.

This project intends to explore the use of artificial intelligence methods and augment medical images with data, potentially aiding in detection, diagnosis, prognosis, treatment responses and disease monitoring.

 

  • Obra3HT – Optimizing Breast Cancer treatment planning workflow: from 3DCRT to hybrid techniques
    PI199-CI-IPOP-35-2023; Budget: 15.000.00€ (2023 – ongoing); PI: Dr. Joana Lencart

Three-dimensional conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are common techniques used in breast cancer radiotherapy. 3DCRT employs multiple radiation beams aimed at the target from different angles, using a multileaf collimator to shape the beam and minimize the dose to nearby critical organs at risk (OAR). IMRT modulates the intensity of each beam to better conform the dose to the target’s shape, often resulting in lower doses to OARs. Hybrid radiotherapy (RT), combining both techniques, is used in Whole Breast (WB) irradiation and Simultaneous Integrated Boost (SIB). This hybrid approach is particularly useful when the target’s concavity involves an OAR, such as the heart, or when the tumor is large or complex, posing challenges for 3DCRT alone in achieving adequate target coverage while keeping OAR doses within tolerance levels.

The project aims to validate and propose the integration of hybrid techniques (3DCRT-IMRT or 3DCRT-VMAT) into institutional radiotherapy protocols for WB irradiation and assess their applicability to other anatomical sites. A selection of breast cancer patients previously treated with 3DCRT, including both left and right breast cases, will be randomly chosen. Clinically valid plans will be generated using hybrid techniques with the service Treatment Planning System (Varian Eclipse v16.1) and EZFluence software to optimize the 3DCRT component. Both AAA and Acuros algorithms will be used for plan calculations. The plans’ validation involves three steps using commercial software and quality control equipment: 1) ClearCheck (Radformation) will automatically extract dosimetric characteristics from the TPS for target coverage and OAR doses; 2) ClearCalc (Radformation) will serve as an independent calculation tool to verify accuracy; 3) Primo, a Monte Carlo treatment planning tool validated in prior projects, will provide additional independent calculations. Furthermore, 729 matrix and Verisoft (PTW), along with other methods, will be used as patient-specific QA tools. The validated plans will be grouped by technique, and a statistical analysis of relevant dosimetric parameters will be performed to compare the techniques.

 

  • DoReMi – Development and implementation of a MRI-only guided radiotherapy workflow
    PI200-CI-IPOP-36-2023; Budget: 13.000.00€ (2023 – ongoing); PI: Dr. Sara Pinto

In the last decade, radiotherapy (RT) planning has increasingly used both computed tomography (CT) and magnetic resonance imaging (MRI). CT provides electron density values for dose calculation, while MRI offers superior soft tissue contrast for better delineation of target volumes and organs at risk (OAR). MRI-only RT is becoming more common as it reduces healthy tissue exposure to CT-derived ionizing radiation, eliminates co-registration errors, and decreases resource use and costs, reducing duplicated efforts between diagnostic radiology and radiotherapy departments.

Planning MRI differs from diagnostic MRI by using larger diameter scanners, flat table tops for MR-compatible immobilization devices, external laser systems, and dedicated quality control and imaging protocols. Introducing MRI-only RT into clinical practice presents challenges such as patient movement during acquisition and ensuring geometric accuracy. Geometric accuracy is crucial for assessing MRI scanners’ suitability for RT planning, especially for radiosurgery/stereotactic radiotherapy (SRS/SRT). Image processing in diagnostic radiology focuses on qualitative tissue contrast rather than millimeter-level anatomical precision. Consequently, radioncologists may use uncorrected or partially corrected MRI scans for SRS/SRT planning. A comprehensive standard procedure for correcting MRI distortion has not been established, though the American Association of Physicists in Medicine (AAPM) is working on guidelines. A clinically viable QA protocol is needed to measure MRI images’ geometric precision and assess long-term stability.

Optimizing MRI protocols for RT planning involves maximizing spatial resolution and tissue contrast, minimizing acquisition time, and maintaining anatomical congruence despite motion. Compromises are necessary as simultaneous optimization of all factors is impossible. The signal-to-noise ratio (SNR) affects the perception of structures in low-resolution images and the distinction of small objects. Since patients are diagnosed before MRI for RT, a weaker SNR may be acceptable if other image quality parameters improve.

High spatial resolution, particularly slice thickness, is needed to distinguish small lesions or structures. However, high resolution alone does not guarantee visibility without sufficient image contrast or SNR. Image optimization requires balancing spatial resolution for adequate SNR and the ability to see fine details while maintaining a reasonable acquisition time. Radiology departments focus on accurate diagnosis, while radiotherapy requires images that support effective, safe treatment. Optimizing MRI for RT is time-consuming, often doubling acquisition time, and may necessitate sacrificing SNR for patient comfort during acquisition.

 

  • RaAITo – Development of a Chatbot for Radiotherapy using Artificial Intelligence Tools
    PI201-CI-IPOP-37-2023; Budget: 15.000.00€ (2023 – ongoing); PI: Dr. Bárbara Barbosa

Faced with the fourth industrial revolution, more specifically the era of the digitalization of society and economy, the digital transition is considered to be an instrument of sustainability for our country, aligned with the development interests/investments of the European Union. In this context, it becomes imperative to develop programs and strategies aimed at boosting digital and economic competitiveness. Recent literature points to Artificial Intelligence (AI) as an increasingly influential scientific area in solving problems in the healthcare sector. AI methods enable problem-solving in clinical settings and support the decision-making process in an automated and intelligent way. Currently, given the growing demand of radiotherapy users to receive quick and efficient answers to their questions when contacting the institution and the high amount of time allocated to specialists, the creation of a chatbot using AI tools is suggested. Conversational chatbots use Natural Language Processing (NLP) and Natural Language Understanding (NLU), applications of AI that enable machines to understand human language and intentions.
For the implementation of this project the action plan would be the development of a chatbot by the research team with the collaboration of a Master’s student and a grant holder.
There are currently several solutions that are highly customizable and easy to implement. For example, Google offers the Healthcare Natural Language API, which is specifically designed to analyze unstructured medical text and is also flexible enough to easily integrate with an institution’s existing internal systems.
As a general rule, the implementation of this technology will require the creation of a dictionary of intentions (database) by the multidisciplinary team of the radiotherapy department that will allow the integration of the different expertise of professionals in this field. Each conversation intent contains:
• a tag (defining what the intent is);
• patterns (sentence patterns for the neural network text classifier);
• possible responses.
The conversational intent definitions are transformed into a model, and a vocabulary structure is built for the chatbot to process the responses.
To increase the quality and scope of the construction of this dictionary of intentions, a survey will also be carried out by professionals from different specialities. In order to ensure the relevance and continuity of the project, quality control and impact measures will be implemented. One possible approach would be a star rating of the chatbot’s performance by the user at the end of the conversation.
approach would be a star rating of the chatbot’s performance by the user at the end of the conversation.
A multidisciplinary approach is required for the management of patients with cancer. A team of physicians, physicists, technicians, and nurses provides patient-centered care and enables decision-making at different points in their treatment. Support services, such as customer service to answer questions, have also become an important part of cancer care. Improving these services means ensuring the quality of the services provided and the continuity of a close relationship between the institution and the patient. This proximity will strengthen the image of excellence and innovation of the IPO Porto, based on the national strategy of administrative modernization and digital transformation.

 

  • LuPET – Lu-177 radiotherapy outcome prediction using image data from Ga-68 PET/CT scans
    PI202-CI-IPOP-38-2023; Budget: 10.000.00€ (2023 – ongoing); PI: Prof. João Santos

The project aims to predict outcomes of Lutetium-177 (Lu-177) radiotherapy in neuroendocrine tumor (NET) patients using image data from Gallium-68 (Ga-68) PET/CT scans. NETs are diverse malignancies originating from neuroendocrine cells, and Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTA-TATE is an effective treatment for inoperable or metastatic cases. However, patient responses vary, necessitating the identification of predictive markers for treatment response. Radiomics, which extracts quantitative features from medical imaging data, offers a promising approach. The project will involve the following steps: Data Collection: Retrospective collection of Ga-68 PET/CT scans and clinical data from NET patients treated with Lu-177 PRRT. Ensure ethical approvals and patient consent for data usage. Image Preprocessing: Standardize the Ga-68 PET/CT images by performing necessary preprocessing steps such as normalization, segmentation, and registration to ensure uniformity and accuracy in feature extraction. Feature Extraction: Utilize radiomics software to extract quantitative features from the preprocessed images. These features may include texture, shape, intensity, and wavelet-based characteristics that describe the tumor’s heterogeneity. Data Analysis: Integrate the extracted radiomic features with clinical data, such as patient demographics, treatment parameters, and outcomes. Perform statistical analysis to identify features significantly correlated with therapy response. Model Development: Develop predictive models using machine learning algorithms. Train the models on a portion of the dataset, validating and testing on separate subsets to ensure robustness. Techniques like cross-validation, regularization, and feature selection will be employed to optimize model performance. Validation: Validate the predictive models using an independent dataset to confirm their generalizability and accuracy. Performance metrics such as accuracy, sensitivity, specificity, and area under the curve (AUC) will be calculated. Interpretation and Reporting: Analyze the model outputs to identify key predictive features and their clinical relevance. Prepare comprehensive reports and visualizations to communicate the findings to clinical stakeholders. Implementation: Develop guidelines and tools for implementing the predictive models in clinical practice. Train clinicians on the use of these tools to enhance treatment planning and decision-making. Evaluation: Continuously evaluate the models’ performance in a clinical setting, making necessary adjustments based on feedback and new data. The successful completion of this project could significantly improve the personalization of Lu-177 PRRT, leading to better outcomes for NET patients.

 

  • TBIVMAT – Implementation of total body irradiation using volumetric modulated arc therapy as part of an institutional hematopoietic stem cell transplantation program
    PI203-CI-IPOP-39-2023; Budget: 45.000.00€ (2023 – ongoing)
    PI : Dra. Anabela Dias

Total body irradiation (TBI) with megavoltage photon beams is used in treating multiple myeloma, leukemias, lymphomas, and some solid tumors, often in combination with chemotherapy as part of conditioning before allogeneic hematopoietic stem cell transplantation. TBI delivers a uniform dose to the entire body, reaching areas like the central nervous system and testicles, which chemotherapy alone cannot. It also allows for customized dosing by shielding or boosting specific regions. Conventional TBI (cTBI) uses large fields with lung blocks to irradiate the entire body in standing or lying-on-the-side positions at extended distances, requiring large, costly vaults. cTBI has long application times and cannot individually spare organs at risk (OARs), leading to significant toxicity.
Advanced techniques aim to selectively target hematopoietic tissues with malignant cells while sparing healthy tissues. Total marrow irradiation (TMI) is a conformal treatment of the skeleton and an alternative to TBI, improving dose homogeneity with inverse optimization algorithms. TMI with volumetric modulated arc therapy (VMAT) avoids cTBI complications while maintaining effectiveness. However, limited preclinical models mean little understanding of the biological differences between TBI and TMI and their effects on bone marrow engraftment.
Studies show VMAT techniques reduce TBI treatment time and improve dose homogeneity, though their use is not widespread. VMAT enhances conformality and homogeneity in dose distribution, optimizing multiple arcs simultaneously for complex plans. Using VMAT for TBI aims to achieve optimal target coverage and sparing of OARs like the lungs, potentially reducing treatment side effects. The challenge is the large planning target volume (PTV), requiring multiple overlapping arc treatments and repositioning due to couch limitations.
This project aims to implement TBI using VMAT in a hematopoietic stem cell transplantation program. A full-body phantom is essential, necessitating the creation of RANDO phantom limbs. Although TBI is delivered supine, patients need repositioning due to couch limits. A secondary objective is to develop a rotatable tabletop system for multi-isocenter plans without repositioning patients. This could lead to high-precision 3D treatment, offering a homogeneous total body dose and sparing critical organs compared to conventional methods.

 

  • SyNTHaX – Synergistic effect of gold Nanoparticles in cancer hybrid Therapeutics: hyperthermia coupled with X-ray irradiation
    PI204-CI-IPOP-40-2023; Budget: 22.600.00€ (2023 – ongoing); PI: Prof. Pedro Teles

In the SyNTHaX project, we will test the synergistic effects of combining GNRT and hyperthermia mediated by AuNPs in MCF-7 cell cultures, which are epithelial cells isolated from the mammary tissue of a 69-year-old white female patient with metastatic adenocarcinoma. This will be done in four different modalities in addition to the control group. In one modality, the cells will be irradiated with 60 keV X-rays and then excited with a pulsed laser optimized for heating the AuNPs. In the next modality, the cells will first be excited with the same laser and then irradiated with 60 keV X-rays. In the third modality, the cells will be irradiated only with 60 keV X-rays, and finally, in the fourth modality, only the laser will be used. Cell viability will be assessed using the Alamar Blue assay. Tissue responses and nanoparticle distributions will be measured spatially and temporally using 3D vascularized microfluidic breast cancer platforms. The AuNPs will be synthesized and characterized at IFIMUP, which already has excellent expertise in the fabrication and characterization of NPs. Their morphology will be optimized for laser heating. Dosimetry calculations will be performed through Monte Carlo simulations using state-of-the-art codes, which will allow for the determination of dose enhancement factors that can be correlated with cell viability.

Publications

Amorim JP; Abreu P.H.; Santos, J.; Müller, H., Evaluating Post-hoc Interpretability with Intrinsic Interpretability, arXiv arXiv:2305.03002, https://doi.org/10.48550/arXiv.2305.03002 [IF: n.a.]

Amorim JP, Abreu PH, Santos J, Cortes M, Vila V, Evaluating the faithfulness of saliency maps in explaining deep learning models using realistic perturbations, Information Processing and Management, 60 (2023) 103225, https://doi.org/10.1016/j.ipm.2022.103225 [IF: 8.6]

Barbosa B, Oliveira C, Bravo I, Couto JG, Antunes L, McFadden S, Hughes C, McClure P, Rodrigues J, Dias A. An investigation of Digital Skills of Therapeutic Radiographers/Radiation Therapists: A European survey of proficiency level and future educational needs. Radiography.2023;29(3):479–88 https://doi.org/10.1016/j.radi.2023.02.009 [IF: 2.6]

Catarina Macedo-Silva, Vera Miranda-Gonçalves, Nuno Tiago Tavares, Daniela Barros-Silva, Joana Lencart, João Lobo, Ângelo Oliveira, Margareta P. Correia, Lucia Altucci, Carmen Jerónimo, Epigenetic regulation of TP53 is involved in prostate cancerradioresistance and DNA damage response signaling, Signal Transduction and Targeted Therapy, 2023, 8:395. [IF 39.3]

Silva, MM, Canha M, Salazar D, Neves JS, Ferreira G, Carvalho D, Duarte H, Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center, Cureus, 2023 Oct 23;15(10):e47506. doi: 10.7759/cureus.47506 [IF: 1.2]

Flood T, O’Neill A, Oliveira C, Barbosa B, Soares A, Muscat K, Guille S, McClure P, Hughes C, McFadden S. Patients’ perspectives of the skills and competencies of Therapy Radiographers/Radiation Therapists (TRs/RTTs) in the UK, Portugal and Malta; a qualitative study from the SAFEEUROPE project. Radiography. 2023;29:S117-S127. https://doi.org/10.1016/j.radi.2023.03.002 [IF: 2.6]

Flood, T., O’Neill, A., Oliveira, C., Barbosa, B., Soares, M. A. L., Muscat, M. K., Guille, S., Mc Clure, P., Hughes, C., & McFadden, S. 2023. “Patients’ perspectives of the skills and competencies of therapy radiographers/radiation therapists (TRs/RTTs) in the UK, Portugal and Malta; a qualitative study from the SAFE Europe project”. Radiography, 29, 1-11. https://doi.org/10.1016/j.radi.2023.03.002 [IF: 2.6]

Julian Malicki, Carla Lopes Castro, Magdalena Fundowicz, Marco Krengli5, Carmen Llacer-Moscardo, Sebastian Curcean, Carles Muñoz Montplet, Luisa Carvalho,Ewelina Konstanty, Tania Hernandez Barragan, Carla Pisani, Istvan Laszlo, Miquel Macià Garau, Marta Kruszyna-Mochalska, Joana Lencart, Dorota Zwierzchowska, Alvar Rosello Serrano, Adelina Brezae, Eva Loureiro Varela, Piotr Milecki, Micol Zannetti, Ovidiu Coza, Eva Gonzalez, Debora Beldì, Ferran Guedea, IROCA-TES: Improving Quality in Radiation Oncology through Clinical Audits — Training and Educationfor Standardization, Reports of Radiotherapy and Oncology, 2023, 28(3):429-432 [IF: 1.2]

Katarina Sjögreen-Gleisner, Glenn Flux, Klaus Bacher, Carlo Chiesa, Robin de Nijs, George C. Kagadis, Thiago Lima, Maria Lyra Georgosopoulou, Pablo Minguez Gabiña, Stephan Nekolla, Steffie Peters, Joao Santos, Bernhard Sattler, Caroline Stokke, Johannes Tran-Gia, Paddy Gilligan, Manuel Bardiès, EFOMP policy statement nº 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy, European Journal of Medical Physics, 116 (2023) 103166, https://doi.org/10.1016/j.ejmp.2023.103166 [IF: 3.4]

Mariana Morais, Vera Machado, Patrícia Figueiredo, Francisca Dias, Rogéria Craveiro, Joana Lencart, Carlos Palmeira, Kirsi S. Mikkonen, Ana Luísa Teixeira, Rui Medeiros, Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiotherapy Sensitivity on Clear Cell Renal Cell Carcinoma, Antioxidants, 2023, 12(12):2051. [IF 7.0]

Maurício J, I. Domingues, J. Bernardino. Comparing Vision Transformers and Convolutional Neural Networks for Image Classification: A Literature Review. Applied Sciences. 2023; 13(9): 5521. [IF: 2.7]

Mendes B, I. Domingues, F. Dias, J. Santos. Cone Beam Computed Tomography Radiomics for Prostate Cancer: Favourable vs Unfavourable Prognosis Prediction. Applied Sciences. 2023; 13(3):1378. [IF: 2.7]

Miriam Seoane Santos, Pedro Henriques Abreu, Nathalie Japkowicz, Alberto Fernández, João Santos, A unifying view of class overlap and imbalance: Key concepts, multi-view panorama, and open avenues for research, Information Fusion 89 (2023) 228–253, https://doi.org/10.1016/j.inffus.2022.08.017 [IF: 18.6]

O Neil A, Hughes C, McClure P, Barbosa B, Muscat K, Oliveira C, Soares AL, McFadden S. 2023. Patient-reported perspectives of therapeutic radiographers when undergoing radiotherapy. A European multi-centre study. Radiography 29:S32-S39. doi:10.1016/j.radi.2023.01.027 [IF: 2.6]

Oliveira C, Barbosa B, Couto JG, Bravo I, Hughes C, McFadden S, Khine R, McNair H. Advanced practice roles of therapeutic radiographers/radiation therapists: An European survey. .Radiography. 2023;29 (2): 261-273. DOI: 10.1016/j.radi.2022.12.003 [IF: 2.6]

Oliveira C, Barbosa B, Couto JG, Bravo I, Hughes C, McFadden S, Khine R, McNair H. Advanced practice amongst therapeutic radiographers/radiation therapists: Exploring the potential of the four pillars: preliminary results from a European perspective. J. Med. Imaging Rad Science 53 (4), S26_27 DOI: 10.1016/j.jmir.2022.10.088 [IF: 1.8]

Pires AM L. Carvalho, A.C. Santos, A.M. Vilaça, A.R. Coelho, F. Fernandes, L. Moreira,J. Lima, R. Vieira, M.J. Ferraz, M. Silva, P. Silva, R. Matias, S. Zorro, S. Costa, S. Sarandão,A.F. Barros, Radiotherapy skin marking with lancets versus electric marking pen (CONFORTATTOO)- 6 Months Results on Cosmesis, Fading, and Patients’ Satisfaction From a Randomized, Doubçe-Blind Trial, Radiography, VOLUME 9, ISSUE 3, 101404, MARCH, 2024 (Published:November 05, 2023) [IF: 2.6]

Pires AM, Borges F, Dias AG, Lencart J, Matos M, Gonçalves J, Paraffin gauze bolus as tissue compensator on photon irradiation for mycosis fungoides – regarding a case study, Journal of Radiotherapy in Practice 22 (e82) 2023. https://doi.org/10.1017/S1460396923000109 [IF: 0.148]

Rodrigues A, N. Rodrigues, J. Santinha, M. V. Lisitskaya, A. Uysal, C. Matos, I. Domingues, N. Papanikolaou. Value of handcrafted and deep radiomic features towards training robust machine learning classifiers for Prediction of Prostate Cancer Disease Aggressiveness. Scientific Reports. 2023; 13(6206). [IF: 4.6]

Soares AL, Buttigieg SC, Bak B, McFadden S, McClure P, Couto JG, Bravo I. A Review of the Applicability of Current Green Practices in Healthcare Facilities. Int J Health Policy Manag. 2023;12:6947. doi: 10.34172/ijhpm.2023.6947 [IF: 2.9]

Soares AL, Buttigieg SC, Couto JG, Bak B, McFadden S, Bravo I. An evaluation of knowledge of circular economy among Therapeutic Radiographers/Radiation Therapists (TR/RTTs): Results of a European survey to inform curriculum design. Radiography (Lond). 2023 Mar;29(2):274-283. doi:10.1016/j.radi.2022.12.006 [IF: 2.6]

Ana Arriaga; Cláudia Gonçalves; P. Teles; Joana Santos; Paula Simãozinho; Patrick Sousa, Establishment of local diagnostic reference levels for abdomen and chest radiographies in the region of Algarve, Portugal, European Journal of Radiology, 170 (2023) 111248, DOI: 10.1016/j.ejrad.2023.111248 [IF: 3.3]

Books, & Book Chapters

M. El Amine Bechar, N. Settouti, and I. Domingues, Deep Learning vs. Super Pixel Classification for Breast Masses Segmentation, Deep Learning for Biomedical Applications, Boca Raton: CRC Press, 2021, pp. 121–156, eBook ISBN9780367855611

Selected publications (up to five)

Amorim JP, Abreu PH, Santos J, Cortes M, Vila V, Evaluating the faithfulness of saliency maps in explaining deep learning models using realistic perturbations, Information Processing and Management, 60 (2023) 103225, https://doi.org/10.1016/j.ipm.2022.103225 [IF: 8.6]

Catarina Macedo-Silva, Vera Miranda-Gonçalves, Nuno Tiago Tavares, Daniela Barros-Silva, Joana Lencart, João Lobo, Ângelo Oliveira, Margareta P. Correia, Lucia Altucci, Carmen Jerónimo, Epigenetic regulation of TP53 is involved in prostate cancerradioresistance and DNA damage response signaling, Signal Transduction and Targeted Therapy, 2023, 8:395. [IF 39.3]

Katarina Sjögreen-Gleisner, Glenn Flux, Klaus Bacher, Carlo Chiesa, Robin de Nijs, George C. Kagadis, Thiago Lima, Maria Lyra Georgosopoulou, Pablo Minguez Gabiña, Stephan Nekolla, Steffie Peters, Joao Santos, Bernhard Sattler, Caroline Stokke, Johannes Tran-Gia, Paddy Gilligan, Manuel Bardiès, EFOMP policy statement nº 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy, European Journal of Medical Physics, 116 (2023) 103166, https://doi.org/10.1016/j.ejmp.2023.103166 [IF: 3.4]

Mendes B, I. Domingues, F. Dias, J. Santos. Cone Beam Computed Tomography Radiomics for Prostate Cancer: Favourable vs Unfavourable Prognosis Prediction. Applied Sciences. 2023; 13(3):1378. [IF: 2.7]

Miriam Seoane Santos, Pedro Henriques Abreu, Nathalie Japkowicz, Alberto Fernández, João Santos, A unifying view of class overlap and imbalance: Key concepts, multi-view panorama, and open avenues for research, Information Fusion 89 (2023) 228–253, https://doi.org/10.1016/j.inffus.2022.08.017 [IF: 18.6]

NATIONAL COLLABORATIONS

Faculty of Sciences of the University of Porto (FCUP)
Institute of Biomedical Sciences Abel Salazar of the University of Porto (ICBAS)
Higher Technical Institute (IST/CTN)
INESC Porto
University of Aveiro (Department of Mechanical Engineering)
University of Coimbra (Center for Informatics and Systems of the University of Coimbra; LIP)
Faculty of Sciences of the University of Lisbon
University of Minho (MEMS)

INTERNATIONAL COLLABORATIONS

Institute of Nuclear Physics PAN; Krakow, Polónia
Institution: Radiation Chemistry and Dosimetry Laboratory; Country: Bijenička c. 54, HR-10000 Zagreb, Croatia
Greek Atomic Energy Commission (EEAE), Dosimetry and Calibration Department; Atenas, Greece
Belgian Nuclear Research Centre, Unit Research in Dosimetric Applications; Belgium
Safe and Free Exchange of EU Radiography Professionals across Europe (SAFE EUROPE); Multi-institutional; European Consortium
European Radiation Dosimetry Group – EURADOS; EURADOS e. V.

Experimental Pathology & Therapeutics Group

The group is dedicated to understanding cancer pathophysiological mechanisms and identifying biomarkers/molecular targets for precision oncology, by combining top-notch multi-omics, genetically engineered cancer cells, and animal models. It develops basic, translational, and clinical cancer research with the aim of improving cancer patient’s clinical management. The group closely collaborates with biopharmaceutical companies and has been actively committed to bringing improvements to health care through innovation, supporting clinical trials, new ventures and graduate training in oncology. It is also devoted to implementing oncology and cancer research units in Portuguese-speaking African countries.

COORDENADOR CIENTÍFICO

Lúcio Lara Santos, MD, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-0521-5655
Senior Surgeon
Associated Professor, Specialist in Oncology Surgery
Email: lucio.santos@ipoporto.min-saude.pt

TEAM
Senior Investigators

José Alexandre Ferreira, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-0097-6148/ 641C-9F20-41B1
Principal Investigator
Coordinator of the research line “Glycobiology of systems applied to cancer”; CEO of the start-up GlycoMatters Biotech (www.glycomatters.com)
Email: jose.a.ferreira@ipoporto.min-saude.pt

Carlos Alberto Palmeira de Sousa, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-4833-2202/ 781B-62F1-B0BA
Técnico Superior de Saúde do Laboratório de Imunologia
Senior Health Technician in the Immunology Laboratory
Coordinator of the research line “Cancer Immunology”; Assistant Professor in Immunology and Histopathology
Email: carlospalmeira@ipoporto.min-saude.pt

Luís Carlos Oliveira Lima, PhD
ORCID ID/ CIÊNCIA ID: 0000-0001-8152-9237/ 9F16-0E29-D9FC
Junior Researcher
Coordinator of the research line “Cancer Biomarker”
Email: luis.carlos.lima@ipoporto.min-saude.pt

 

Junior Researchers

Andreia Filipa Ferreira Peixoto, PhD
ORCID ID/ CIÊNCIA ID: 0000-0001-9514-0775/ 361D-5B5E-A5C1
Email: andreia.peixoto@ipoporto.min-saude.pt

 

Invited Researchers

Cristina Patrícia Mendes Santos, PhD
ORCID/ CIÊNCIA ID: 0000-0003-1437-9157/ D211-A545-54FC
Psycologist @ Associação Fraunhofer Research Portugal
Email: mendessantos.cristina@gmail.com

Elisabete Cristina Nunes Fernandes, PhD
ORCID/ CIÊNCIA ID: 0000-0002-9907-7432/ E31A-6197-4349
Science manager @UFP – University Fernando Pessoa
Email:

Maria do Céu dos Santos Silva Costa, PhD
ORCID/ CIÊNCIA ID: 000-0003-3766-2887/ 1915-FDC2-099B
Assistant Professor @ UFP – University Fernando Pessoa
Email: ccosta@ufp.edu.pt

Maria do Rosário Lima Viseu de Carvalho Pinto Leite, PhD
ORCID/ CIÊNCIA ID: 000-0003-4128-0494/ 5E1F-A422-C16D
Clinical Laboratory Geneticist @ CHTMAD
Email: mlleite@chtmad.min-saude.pt

Otília Pereira-Lopes, PhD
ORCID/ CIÊNCIA ID: 0000-0002-6199-4091/ 8C19-5295-FF32
Assistant Professor @ UFP – University Fernando Pessoa
Email: otilia@ufp.edu.pt

Pâmela Cristina Carvalho Borges, PhD
ORCID/ CIÊNCIA ID: 0000-0002-4491-9874/ F01A-BAE5-7AB6
Foreigner Researcher – Principal Investigator of Molecular Biology Lab @ Agostinho Neto University Hospital, Cape Verde
Email: palu15.18@gmail.com

Sofia do Rosário Alves Pereira, PhD
ORCID/ CIÊNCIA ID: 000-0002-3633-397x/ CF1A-9493-5C42
Assistant Professor @ UFP – University Fernando Pessoa
Email: sofia@ufp.edu.pt

PhD Students

Adriana Carneiro, MSc
ORCID/ CIÊNCIA ID: 0000-0003-1905-6250/ 481E-1A5C-FD18
INL Braga & CI-POP
Email: adriana.carneiro@ipoporto.min-saude.pt

Ana Carolina Fernandes Vieira de Castro, MSc
ORCID/ CIÊNCIA ID: 0000-0001-8156-4470/ BE18-11D8-B606
CI-IPOP
Email: ana.castro@ipoporto.min-saude.pt

Andreia Rafaela Linhares Miranda, MSc
ORCID/ CIÊNCIA ID: 0000-0002-5441-4888/ 1718-50AE-1648
CI-IPOP
Email: i37220@ipoporto.min-saude.pt

Catarina Alexandra da Rocha Rodrigues, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1305-8055/ 321E-40C9-FC31/ 321E-40C9-FC31
CI-IPO & i3S
Email: catarina.rodrigues@ipoporto.min-saude.pt

Catarina Alves Pinto, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1465-7666/ 2F1F-8115-52CE
CI-IPOP & ICBAS & University of Tokyo
Email: up201402615@edu.icbas.up.pt

Clara Alice Gentil Daher Mota, MSc
ORCID/ CIÊNCIA ID: 0000-0002-2938-1623/ 1611-4013-2CBB
FADEUP &CI-IPOP
Email: clara.mota@ipoporto.min-saude.pt

Cristiana Milhazes Gaiteiro, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5438-1679/ 6717-DB97-FF86
CI-IPOP
Email: i12812@ipoporto.min-saude.pt

Daniel Mateus Gonçalves, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5388-870/ 9D14-B66F-A1CF
Instituto Superior Técnico & CI-IPOP
Email: dmateusgoncalves@tecnico.ulisboa.pt

Daniela Rocha Santos, MSc
ORCID/ CIÊNCIA ID: 0000-0003-1081-5142/ 4617-DBEA-8AE6
CI-IPOP
Email: daniela.r.santos@ipoporto.min-saude.pt

Dylan Gomes Ferreira, MSc
ORCID/ CIÊNCIA ID: 0000-0001-9224-0121/ AA12-CF31-3A82
CI-IPOP & CIMA Institute
Email: i38795@ipoporto.min-saude.pt

Eliana Janine de Paiva Soares, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1586-7120/ 9A1D-8326-6C19
CI-IPOP& UA
Email: eliana.paiva.soares@ipoporto.min-saude.pt

João Miguel Monteiro Antunes, MSc
ORCID/ CIÊNCIA ID: 0000-0002-9904-5115/ E110-6373-AB6D
FADEUP & CI-IPOP
Email: joao.monteiro.antunes@ipoporto.min-saude.pt

Mafalda Barbosa Pedrosa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-3222-731X/ CC1F-AF12-787C
FADEUP & CI-IPO & UA
Email: i37305@ipoporto.min-saude.pt

Maria de Fátima Sousa e Santos, MSc
ORCID/ CIÊNCIA ID: 0000-0003-3796-2054/ CB1E-EE01-ED1C
CI-IPOP
Email: maria.fatima.santos@ipoporto.min-saude.pt

Mariana Pinto de Sousa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5232-2384/ 151A-5FC2-8034
CI-IPOP
Email: mariana.p.sousa@ipoporto.min-saude.pt

Marta Filipa Relvas dos Santos, MSc
ORCID/ CIÊNCIA ID:: 0000-0001-5764-5414/ EE19-E89D-2D92
CI-IPOP & FCUP
Email: marta.relvas.santos@ipoporto.min-saude.pt

Michelle Shereen Alves Castanheira, MSc
ORCID/ CIÊNCIA ID:: 0009-0005-7368-687X /4311-D422-CF14
GRAQ- REQUIMTE & CI-IPOP
Email: michelle_castanheira@hotmail.com

Nuno Henrique Oliveira Jorge, MSc
ORCID/ CIÊNCIA ID: 0000-0003-5531-0557/ D716-29E8-991
FADEUP &CI-IPOP
Email: nuno.jorge@ipoporto.min-saude.pt

Patrícia Pinto de Pinho, MSc
CIÊNCIA ID:: D21B-B93A-6001
CITAB & CI-IPOP
Email: patriciapintopinho@hotmail.com

Pedro Miguel dos Reis Cruz, MD, MSc
ORCID/ CIÊNCIA ID: 0000-0001-8813-0632/ 0610-621F-B88A
CI-IPOP
Email: pedro.reis.cruz@ipoporto.min-saude.pt

Rui Filipe Neves Freitas, MSc
ORCID/ CIÊNCIA ID: 0000-0003-0723-8719/ 2B13-9E7D-E20B
CI-IPOP & I3s
Email: rui.freitas@ipoporto.min-saude.pt

Samuel da Silva Barbosa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5364-7340/ 0713-CF7A-0417
FADEUP & CI-IPOP
Email: i37306@ipoporto.min-saude.pt

Sofia Ribeiro Cotton, MSc
ORCID/ CIÊNCIA ID: 0000-0002-8112-5619/ 081F-D38F-8B7A
CI-IPOP & I3s
Email: sofia.ribeiro.cotton@ipoporto.min.saude.pt

Research Assistants

Beatriz Marinho Santos, MSc
ORCID/ CIÊNCIA ID: 0009-0004-2783-4950/ 071C-C3F1-1D95
Email: beatriz.santos@ipoporto.min-saude.pt

Beatriz da Silva Matos, MSc
ORCID/ CIÊNCIA ID: 0000-0002-9333-5525/ 8E17-4276-A691
Email: beatriz.matos@ipoporto.min-saude.pt

Eduardo da Silva Ferreira, MSc
ORCID/ CIÊNCIA ID: 0009-0003-3258-8451/ E61B-3A6A-E8AE
Email: i37310@ipoporto.min-saude.pt

Mariana Gonçalves Eiras, MSc
ORCID/ CIÊNCIA ID: 0009-0006-7483-4771/ F310-BAED-C2E9
Email: mariana.eiras@ipoporto.min-saude.pt

Martina Dourado Gonçalves, MSc
ORCID/ CIÊNCIA ID: 0009-0004-6311-3990/ C410-3A72-CC85
Email: martina.goncalves@ipoporto.min-saude.pt

MSc Students

Camila Adriana Gonçalves Lourenço
CIÊNCIA ID: 391C-D972-B9EA
Email: camila.lourenco@ipoporto.min-saude.pt

Débora Filipa Pinto
CIÊNCIA ID: 2619-D353-8599
Email: debora.pinto@ipoporto.min.saude.pt

Other collaborators

Dora Maria Barrocas Bernardo, MSc, Oncology pharmacist
ORCID/ CIÊNCIA ID: 0000-0002-9755-4362/ 5B17-1115-3B7A
Luís Pedro Fernandes Afonso, MSc, Pathologist
ORCID/ CIÊNCIA ID: 0000-0002-6354-7332/ FA1F-3698-B309
Mariana Macedo Alves Peyroteo Gomes, MD, MSc, Surgeon
ORCID/ CIÊNCIA ID: 0000-0002-0941-2533
Pedro Carvalho Martins, MD, MSc, Surgeon
ORCID/ CIÊNCIA ID: 0000-0002-1828-078X

Aims

Foreseeing precise clinical interventions, the group has four teams:
The Infection in Cancer and Clinical Translation team aims to study the carcinogenesis caused by infectious agents foreseeing clinical intervention. It also focuses on defining personalized risk mitigation programs (e.g. perioperative care).
The systems cancer glycobiology team dedicates to understanding cancer glycosylation by integrating multi-omics approaches and identifying cancer specific signatures for patient stratification and targeted interventions.
The cancer immunology team focuses on mechanisms of immunotherapy resistance and pre-clinical assessment of combination therapies in cellular and animal models.
The cancer biomarkers team studies circulating cancer cells and non-invasive biomarkers envisaging precision oncology.

PROJECTS WITH EXTERNAL FUNDING

RESOLVE: Rational Design of Multivalent Glycocode-Inspired Nanovaccines for Gastric Cancer Immunotherapy
Funded by FCT
Ref: DOI: 10.54499/PTDC/MED-OUT/2512/2021
Period: 01/01/2022 – 31/12/2024
Budget: 128 305.00€
PI: José Alexandre Ferreira

RESOLVE aims at a comprehensive interrogation of the gastric cancer glycoproteome for unique molecular signatures to improve patient stratification. It also plans to translate clinically relevant signatures into innovative cancer glycovaccines exploiting proprietary cutting-edge glycoengineered nanovehicles. These new generation of glycosylated vaccine vehicles can specifically deliver immunogenic cargos to antigen presenting cells, unleashing otherwise compromised immune responses against cancer cells. The objective is to setup the pre-clinical basis for an innovative immunotherapy for cancer.

Publications

Peixoto A, Miranda A, Santos LL, Ferreira JA. A roadmap for translational cancer glycoimmunology at single cell resolution. J Exp Clin Cancer Res. 2022 41(1):143. doi: 10.1186/s13046-022-02335-z.

 

REVERENT: Pre-clinical Validation of a Glycocode-inspired Vaccine for Bladder Cancer Immunotherapy
Funded by FCT
Ref: 2022.03621.PTDC
Period:01/03/2023 – 31/08/2024
Budget: 49 507.07€
PI: Andreia Peixoto Co-PI: José Alexandre Ferreira

The project aims to validate a glycovaccine for bladder cancer in a pre-clinical context, using relevant animal tumor models, with the translational intent for clinical studies.

Phosphoproteomics of hypoxic and glucose deprived bladder cancer cells: the missing link towards systems oncology
Funded by European Proteomics Infrastructure Consortium
Ref: EPIC-XS-0000341
Period:01/06/2021 – 31/05/2023
PI: José Alexandre Ferreira in collaboration with Heck’s Lab at Utrecht University

Hypoxia resulting from ineffective vascularization due to uncontrolled cell growth is a relevant microenvironmental feature of more aggressive tumours, driving main cancer hallmarks. This event is accompanied by nutrient shortage, however the molecular and functional adaptations experienced by cancer cells under both oxygen and nutrient depletion remains poorly understood. Multi-omics systems biology approaches, with emphasis on phosphoproteomics and glycoproteomics, are being used to comprehensively characterize hypoxic microenvironments envisaging precision interventions.

Publications

Peixoto A, Freitas R, Ferreira D, Relvas-Santos M, Paulo P, Cardoso C, Soares J, Gaiteiro C, Palmeira C, Teixeira F, Ferreira R, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation. bioRvx 2021 doi: https://doi.org/10.1101/2021.02.14.431133

 

IPOScore: Predicting the risk of complications of surgical treatment and define prognosis of cancer patients through clinical and biopathological data integration
Funded by FCT
Ref: DSAIPA/DS/0042/2018
Period:01/01/2019 – 31/07/2022
Budget: 31 163.00€
PI: Andreia Peixoto Co-PI: José Alexandre Ferreira

This project intends to apply an innovative approach based on data-driven modeling that integrates clinical, biopathological and physiological data of patients with cancer to predict the risk of (post-)operative complications. The expected outcome is the creation of an user-friendly online platform, which includes a database to store/manage the data collected in a structured format, computational approaches and prediction models to calculate a specific risk index score for the Portuguese population. The platform will provide an added-value to surgeons in oncological hospitals as an intelligent clinical decision support system.

Publications

Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA. Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm. 2019 570:118646. doi: 10.1016/j.ijpharm.2019.118646.
Fernandes A, Rodrigues J, Lages P, Lança S, Mendes P, Antunes L, Santos CS, Castro C, Costa RS, Lopes CS, da Costa PM, Santos LL. Root causes and outcomes of postoperative pulmonary complications after abdominal surgery: a retrospective observational cohort study. Patient Saf Surg. 2019 13:40. doi: 10.1186/s13037-019-0221-5.
Fernandes E, Sores J, Cotton S, Peixoto A, Ferreira D, Freitas R, Reis CA, Santos LL, Ferreira JA. Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics. 2020 10(11):4903-4928. doi: 10.7150/thno.42480.
Fernandes A, Rodrigues J, Antunes L, Lages P, Santos CS, Moreira-Gonçalves D, Costa RS, Sousa JA, Dinis-Ribeiro M, Santos LL. Development of a preoperative risk score on admission in surgical intermediate care unit in gastrointestinal cancer surgery. Perioper Med (Lond). 2020 9:23. doi: 10.1186/s13741-020-00151-7.
Sousa Menezes A, Fernandes A, Rocha Rodrigues J, Salomé C, Machado F, Antunes L, Castro Silva J, Monteiro E, Lara Santos L. Optimizing classical risk scores to predict complications in head and neck surgery: a new approach. Eur Arch Otorhinolaryngol. 2021 278(1):191-202. doi: 10.1007/s00405-020-06133-1.

PROTECT: Prehabilitation to enhance cancer treatment in patients with adenocarcinoma of the gastroesophageal junction and the stomach
Funded by FCT
Ref: PTDC/SAU-DES/7945/2020
Period: 01/01/2021 – 31/12/2023
Budget: 135 695.00€
PI: Lúcio Lara Santos

The PROTECT project envisions the multimodal prehabilitation of proximal gastric and gastroesophageal junction cancer patients to minimize the burden without compromising the safety and efficacy of anti-cancer treatment.

DCMatters: Combination of Dendritic Cell Vaccine with Immune Checkpoint Inhibitors as First-Line Therapy in Patients
Funded byFEDER
Ref: NORTE-01-0247-FEDER-047212
Budget: 822 007.92€
PI: Lúcio Lara Santos

The DCMatters project aims to develop and manufacture a new generation of dendritic cell (DC) vaccines with greater capacity to induce an anti-tumour response, by optimizing the manufacturing method using chemoinformatic tools and validating it in vitro and in vivo.

Laserthermia: Synergistic antitumor effect of combined laser thermotherapy and immunomodulators in malignant melanoma
Funded by Clinical Laserthermia Systems AB
Ref: PI 130-CI-IPOP-125-2019
Budget: 79 347.64€
PI: Carlos Alberto Palmeira de Sousa Co-PI: Lúcio Lara Santos

The Laserthermia project aims to evaluate the synergistic antitumor effect of laser-based thermotherapy and clinically implemented immunomodulators in poorly immunogenic B16F10 melanoma mouse models.

PROJECTS WITH INTERNAL FUNDING

OptimizingLiverMet: Immunological and circulating tumour cells evaluation in colorectal cancer liver metastasis
REF.: PI 77-CI-IPOP-47-2016
Budget: 47 172.39€
PI: Lúcio Lara Santos Co-PI: Luís Lima

Colorectal cancer is common in Portugal, often leading to liver metastases. Hepatic resection is a primary treatment, with recent advances in systemic therapies improving prognosis. However, challenges like liver recurrences and adverse events persist. Immunotherapy, especially with checkpoint inhibitors like Pembrolizumab, has shown promise for cancers with high mutational loads. Our study aims to analyze immune markers in primary tumors and liver metastases, and assess circulating tumor cells in blood, to optimize treatment strategies for colorectal cancer patients with liver metastases.

GlycoBodies: Development of monoclonal antibodies for chemoresistant bladder cancer based on glycobiomarkers
Funded by IPO Research Center
Ref: CI-IPOP-58-2015
Budget: 223 950.99€
Period:01/01/2015 – 31/12/2024
PI: José Alexandre Ferreira Co-PI: Lúcio Lara Santos

The project devotes to a comprehensive characterization of the bladder cancer glycome and glycoproteome across the multiple pathological manifestations of the disease, with emphasis on tumours not responding to chemotherapy. The overall aim is to identify cancer specific signatures and develop theranostic antibodies for aggressive cells precise targeting.

Publications

Azevedo R, Soares J, Gaiteiro C, Peixoto A, Lima L, Ferreira D, Relvas-Santos M, Fernandes E, Tavares A, Cotton S, Daniel-da-Silva AL, Santos LL, Vitorino R, Amado F, Ferreira JA. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. Talanta. 2018 184:347-355. doi: 10.1016/j.talanta.2018.03.028.

Azevedo R, Soares J, Peixoto A, Cotton S, Lima L, Santos LL, Ferreira JA. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018 36(5):221-236. doi: 10.1016/j.urolonc.2018.02.004.

Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. Front Oncol. 2019 9:380. doi: 10.3389/fonc.2019.00380.

Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA. Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm. 2019 570:118646. doi: 10.1016/j.ijpharm.2019.118646.

Fernandes E, Sores J, Cotton S, Peixoto A, Ferreira D, Freitas R, Reis CA, Santos LL, Ferreira JA. Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics. 2020 10(11):4903-4928. doi: 10.7150/thno.42480.

Fernandes E, Freitas R, Ferreira D, Soares J, Azevedo R, Gaiteiro C, Peixoto A, Oliveira S, Cotton S, Relvas-Santos M, Afonso LP, Palmeira C, Oliveira MJ, Ferreira R, Silva AMN, Lara Santos L, Ferreira JA. Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells. Cancers (Basel). 2020 12(4):861. doi: 10.3390/cancers12040861.

Ferreira JA, Relvas-Santos M, Peixoto A, M N Silva A, Lara Santos L. Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics. 2021 19(1):25-43. doi: 10.1016/j.gpb.2021.03.005.

Peixoto A, Ferreira D, Azevedo R, Freitas R, Fernandes E, Relvas-Santos M, Gaiteiro C, Soares J, Cotton S, Teixeira B, Paulo P, Lima L, Palmeira C, Martins G, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. J Exp Clin Cancer Res. 2021 40(1):191. doi: 10.1186/s13046-021-01988-6.

Cotton S, Ferreira D, Soares J, Peixoto A, Relvas-Santos M, Azevedo R, Piairo P, Diéguez L, Palmeira C, Lima L, Silva AMN, Lara Santos L, Ferreira JA. Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness. Int J Mol Sci. 2021 22(4):1664. doi: 10.3390/ijms22041664.

Freitas R, Relvas-Santos M, Azevedo R, Soares J, Fernandes E, Teixeira B, Santos LL, Silva AMN, Ferreira JA. Single-pot enzymatic synthesis of cancer-associated MUC16 O-glycopeptide libraries and multivalent protein glycoconjugates: a step towards cancer glycovaccines. New Journal of Chemistry 45 2021, 9197-9211, doi:10.1039/d0nj06021f.

Peixoto A, Cotton S, Santos LL, Ferreira JA. The Tumour Microenvironment and Circulating Tumour Cells: A Partnership Driving Metastasis and Glycan-Based Opportunities for Cancer Control. Adv Exp Med Biol. 2021 1329:1-33. doi: 10.1007/978-3-030-73119-9_1.

Peixoto A, Freitas R, Ferreira D, Relvas-Santos M, Paulo P, Cardoso C, Soares J, Gaiteiro C, Palmeira C, Teixeira F, Ferreira R, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation. bioRvx 2021 doi: https://doi.org/10.1101/2021.02.14.431133.

Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, Brandão A, Fernandes E, Azevedo R, Palmeira C, Freitas R, Miranda A, Osório H, Prieto J, Lima L, Silva AMN, Santos LL, Ferreira JA. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022 12(7):3150-3177. doi: 10.7150/thno.67409.

Peixoto A, Miranda A, Santos LL, Ferreira JA. A roadmap for translational cancer glycoimmunology at single cell resolution. J Exp Clin Cancer Res. 2022 41(1):143. doi: 10.1186/s13046-022-02335-z.

Selected publications (up to five)

Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Santos B, Gonçalves M, Quintas S, Peixoto A, Palmeira C, Silva AMN, Santos LL, Oliveira MJ, Sarmento B, Ferreira JA. Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy. ACS Nano 2024 18(14):10088-10103. doi: 10.1021/acsnano.3c12487; PMID: 38535625

Freitas R, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Ferreira E, Gaiteiro C, Soares J, Cotton S, Gonçalves M, Eiras M, Santos B, Palmeira C, Correia MP, Oliveira MJ, Sarmento B, Peixoto A, Santos LL, Silva AMN, Ferreira JA. A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy. J Control Release 2024 367:540-556. doi: 10.1016/j.jconrel.2024.01.065; PMID: 38301927

Carneiro A, Piairo P, Matos B, Santos DAR, Palmeira C, Santos LL, Lima L, Diéguez L. Minimizing false positives for CTC identification. Anal Chim Acta. 2024 1288:342165. doi: 10.1016/j.aca.2023.342165; PMID: 38220297
Santos DAR, Gaiteiro C, Santos M, Santos L, Dinis-Ribeiro M, Lima L. MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening-A Comprehensive Review. Int J Mol Sci. 2023 24(13):11023. doi: 10.3390/ijms241311023. PMID: 37446201;

Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, Brandão A, Fernandes E, Azevedo R, Palmeira C, Freitas R, Miranda A, Osório H, Prieto J, Lima L, Silva AMN, Santos LL, Ferreira JA. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics 2022 12:3150. doi: 10.7150/thno.67409; PMID: 35547758

NATIONAL COLLABORATIONS

André Silva – Faculty of Sciences of University of Porto
Bruno Neves – University of Aveiro
Celso Reis; Cristina Xavier; Fátima Gartner; Isabel Castro; João Vinagre; Luísa Pereira; Maria Helena Vasconcelos; Maria José Oliveira; Paula Soares; Raquel Almeida; Sérgia Velho; Nuno Mendes – i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto
Daniel Moreira Gonçalves – Faculty of Desport of University of Porto
Francisco Amado, Rita Ferreira, Rui Vitorino – Chemistry Department, University of Aveiro
Lorena Dieguez – International Iberian Nanotechnology Laboratory (INL)
Lucília Saraiva – School of Medicine and Biomedical Sciences of University of Porto
Marlene Santos – The School of Health of Polytechnic Institute of Porto
Miguel Oliveira – University of Minho – 3B’s; Braga
Paula Oliveira – University of Trás-os-Montes and Alto Douro
Paula Videira, Angelina Palma, Rafael Costa – NOVA School of Science and Technology, NOVA University Lisbon
Rui Henriques – IST Técnico-University of Lisbon

INTERNATIONAL COLLABORATIONS

André Carvalho – International Agency for Research on Cancer/ World Health Organization; France
Bruno Vedrine – Oncocellex at BUSI Incubateur d’Entreprises Auvergne; France
Carla Carrilho – Facuty of Medicine of University Eduardo Mondlane; Mozambique
Fernando Miguel – Angolan Institute for Cancer Control – IACC, Angola
Giovanni De Manzoni – University of Verona; Italy
Hervé Luche – French Institute of Health and Medical Research | Inserm, France
Isabel M. dos Santos Silva – London School of Hygiene & Tropical Medicine; United Kingdom
Jesus Prieto, Juan José Lasarte – Center for Applied Medical Research (CIMA) of the University of Navarre; Spain
João Curado – Flomics; Spain
Laura Bermejo – Ramón y Cajal Institute for Health Research (IRYCIS); Spain
Luke Cossins – Universal Biosensors (UBI); Australia
Noel Miranda – Leiden University Medical Center (LUMC); Netherlands
Rita Azevedo – Institut Pasteur; France
Rogier Louwen – CCassured; Netherlands
Yvette van kooyk – Amsterdam UMC, Vrije Universiteit Amsterdam; Netherlands

Cancer Genetics Group

The Cancer Genetics Group studies the interplay between inherited cancer predisposition and the pattern of acquired genetic alterations that give rise to cancer, to understand the mechanisms of tumor initiation and progression and their role in therapy response and resistance. In fact, the fields of germline and somatic genetics are progressively more interconnected, as exemplified by shared mutation signatures that might have similar predictive value for targeted cancer therapy. Several biologically and clinically relevant tumor models are studied, with emphasis on prostate cancer. It is a multidisciplinary research group that includes medical doctors, pharmacists, biochemists and biologists, all specialized in cancer genetics.

SCIENTIFIC COORDINATOR

Manuel R. Teixeira, MD, PhD
ORCID ID/Ciência ID: 0000-0002-4896-5982/4D1D-1F29-9100
Research Coordinator/ Director of the Department of Laboratory Genetics/ Guest Full Professor (Medical Genetics and Cancer Genetics), ICBAS – School of Medicine and Biomedical Sciences, University of Porto
Email: manuel.teixeira@ipoporto.min-saude.pt

TEAM
SENIOR INVESTIGATORS

Paula Paulo, PhD
ORCID ID/Ciência ID: 0000-0001-8387-2127/F514-C818-E2FF
Assistant Researcher (2023.14811.TENURE.003)
Email: paula.paulo@ipoporto.min-saude.p

JUNIOR RESEARCHERS

Andreia Brandão, PhD
ORCID ID/Ciência ID: 0000-0003-0938-1543/EA13-D4E6-CDE1
Junior Researcher (2021.03835.CEECIND)
E-mail: andreia.aguiar.brandao@ipoporto.min-saude.pt

Manuela Pinheiro, PhD
ORCID ID/Ciência ID: 0000-0001-8228-3435/0216-6A5F-4983
LAB1 Manager (UID/00776/2025| https://doi.org/10.54499/UID/00776/2025)
E-mail: Manuela.Pinheiro@ipoporto.min-saude.pt

OTHERS RESEARCHERS

Ana Barbosa, PhD
ORCID / Ciência ID: 0000-0002-2307-1018/ E519-6872-5FE9
Clinical Biologist
E-mail: ana.barbosa@ipoporto.min-saude.pt

Ana Peixoto, PhD
ORCID /Ciência ID: 0000-0002-1404-5897 / 2014-3C52-DAC7
Oncology Pharmacist
E-mail: analuisamoura@ipoporto.min-saude.pt

Marta Cardoso, PhD 
(PI210-CI-IPOP-42-2023-RAS-BRAF)
ORCID / Ciência ID: 0000-0002-3633-1659/ EC1A-8211-2BDE
Clinical Biologist
E-mail: marta.cardoso@ipoporto.min-saude.pt

Associated Researchers

Sofia Maia, MD, PhD
ORCID/Ciência ID: 0000-0003-1837-8258 /8713-CBDB-1CD0
Genetician
Coimbra University Hospital
E-mail: s.maia@chuc.min-saude.pt

PhD Students with External Funding

Supervision

Elsa Paiva, MSc
(FCT UI/BD/154819/2023)
ORCID/Ciência ID: 0009-0007-2556-6878 /8214-06A6-66AB
E-mail: i36026@ipoporto.min-saude.pt

Co-Supervision

Mariana Gonçalves Eiras, MSc
(FCT 2024.04511.BD, in collaboration with Experimental Pathology & Therapeutics Group – EPTG & Precancerous Lesions & Early Cancer Management – PRECAM)
ORCID /Ciência ID: 0009-0006-7483-4771/F310-BAED-C2E9
E-mail: mariana.eiras@ipoporto.min-saude.pt

Roberto Miguel Pais Pinto, MSc
(FCT 2024.04316.BDANA, in collaboration with Experimental Pathology & Therapeutics Group – EPTG)
ORCID/Ciência ID: 0009-0001-7167-6249/ 5815-78B1-E99B
E-mail: roberto.pinto@ipoporto.min-saude.pt

Tatiana Almeida, MSc
(FCT 2024.00816.BD, in collaboration with Precancerous Lesions & Early Cancer Management – PRECAM)
ORCID/Ciência ID: 0000-0002-9444-8257 /CD18-88C4-CE90
E-mail: tatiana.almeida@ipoporto.min-saude.pt

PhD Students # IPO Porto Staff

Supervision

Carla Pinto, MSc
(FCT Doutor. AP 2024,16310DAP)
ORCID/Ciência ID: 0000-0001-8689-3388 / 271F-E46E-86E8
Clinical Biologist
E-mail: carla.a.pinto@ipoporto.min-saude.pt

Research Assistants/Technicians

Inês Sá, MSc
(PRECISER-COMPETE2030-FEDER-00721400)
ORCID/Ciência: 0009-0006-7450-3817/ 351B-2E0C-0FBE
E-mail: ines.sa@ipoporto.min-saude.pt

MSc Students

2026/2027

Supervision

Mariana Camões, BSc, Master in Biomedical Research, UC

Hugo Silva, BSc, Master in Oncology, ICBAS-UP

 

2025/2026

Supervision

Afonso Soares, BSc, Master in Oncology, ICBAS-UP

OTHER COLLABORATORS

Beatriz Pinheiro, MSc, Clinical Biologist

Carla Escudeiro, MSc, Clinical Biologist

Catarina Santos, MSc, Clinical Biologist

Cecília Correia, MSc, Clinical Biologist

Gabriela Soares, MD, Genetician

Isabel Santos, MSc, Clinical Biologist

Joana Vieira, MSc, Clinical Biologist

João Silva, MD, Genetician

Lurdes Torres, MSc, Clinical Biologist

Patrícia Arinto, MSc, Clinical Biologist

Susana Bizarro, MSc, Clinical Biologist

Susana Lisboa, MSc, Clinical Biologist

Vanessa Almeida, MSc, Clinical Biologist

AIMS

The main lines of research for the period 2024-2026 are the following:
1. To further characterize the contribution to carcinogenesis of the PRUNE2, BUB1B and IPO4 genes, which we have recently uncovered as candidate prostate cancer predisposition genes contributing to explain the missing heritability of this disease.
2. To understand the polygenic basis of hereditary predisposition to prostate cancer using a multi-omics integrative approach combining genomic and transcriptomic strategies.
3. To use cell-based strategies to screen genetic variants and compounds targeting cilia-related genes for prostate cancer development and therapy.
4. To evaluate the potential utility of anti-EGFR therapies in ETS-positive subtypes of prostate cancer.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)
SELECTED PUBLICATIONS (up to five):

Paiva EG, Orr B, Azeredo A, Brandão A, Teixeira MR, Paulo P. EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer. Mol Oncol. 2025;19(11): p.3287-3304. doi: 10.1002/1878-0261.70069. PMID: 40808640.

Silva MP, Ferreira LT, Brás NF, Torres L, Brandão A, Pinheiro M, Cardoso M, Resende A, Vieira J, Palmeira C, Martins G, Silva M, Pinto C, Peixoto A, Silva J, Henrique R, Maia S, Maiato H, Teixeira MR, Paulo P. BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability. J Biomed Sci. 2024; 31(1):74. doi: 10.1186/s12929-024-01056-z. PMID: 39014450.

Cardoso M, Maia S, Brandão A, Sahasrabudhe R, Lott P, Belter N, Carvajal-Carmona LG, Paulo P, Teixeira MR. Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene. Br J Cancer. 2023; 128(6):1077-1085. doi: 10.1038/s41416-022-02125-6. PMID: 36564567.

Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, Batra J, Apcb BioResource, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, The Impact Study Steering Committee And Collaborators, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ruyck K, Razack A, Newcomb LF, Canary Pass Investigators, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, The Profile Study Steering Committee, The Practical Consortium, Teixeira MR. The CHEK2 variant c.349A>G is associated with prostate cancer risk and carriers share a common ancestor. Cancers (Basel). 2020; 12(11):3254. doi: 10.3390/cancers12113254. PMID: 33158149.

Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, Teixeira MR. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. PLoS Genet. 2018; 14(4):e1007355. doi: 10.1371/journal.pgen.1007355. PMID: 29659569.

PATENTS

(2012) Methods and biomarkers for detection of bladder cancer; US 20130210011/ EP 2630261 A1/ WO 2012052844 A1 (in collaboration Oslo University Hospital).

NATIONAL COLLABORATIONS

Carla Oliveira, PhD | i3S
Hélder Maiato, PhD | i3S
Joana Paredes, PhD | i3S
José Bessa, PhD | i3S

INTERNATIONAL COLLABORATIONS

Luis G Carvajal-Carmona, PhD | UC Davis Genome Center, USA
Rosalind Eeles, MD, PhD (PRACTICAL consortium and IMPACT study) | Institute of Cancer Research, UK
Georgia Chenevix-Trench, PhD, FAA (CIMBA consortium) | QIMR Berghofer Medical Research Institute, Australia
Douglas Easton, PhD (BCAC consortium) | University of Cambridge, UK
Amanda Spurdle, PhD (ENIGMA consortium) | QIMR Berghofer Medical Research Institute, Australia
Nicoline Hoogerbrugge, MD, PhD (European Reference Network on Genetic Tumour Risk Syndromes, GENTURIS) | Radboud University Medical Center, The Netherlands

*The information described in the group is the sole responsibility of the respective coordinator.

Molecular Oncology & Viral Pathology Group

The main aim of the Group, established in 2002, is the characterization of molecular mechanisms associated with cancer development and response to treatment, through the identification of molecular biomarkers, such as genetic polymorphisms, mRNAs, microRNAs, LncRNAs and viral genomes. Within the scope of Precision Medicine, the Group is focused on the study and identification of circulating biomarkers, analyzed by minimally invasive techniques, with clinical applicability, focusing its studies on the definition of risk groups, optimization of therapeutic strategies and study of the communication network established between hosts and tumor microenvironment.

SCIENTIFIC COORDINATOR

Rui Medeiros, PharmD, PhD
ORCID ID/ CIÊNCIA ID: 0000-0003-3010-8373 / C51F-5DBE-9C51
Head of Molecular Oncology and Viral Pathology Group | Director of Research Department from Portuguese League Against Cancer – North Branch | Board member European Cancer Organization
Email: ruimedei@ipoporto.min-saude.pt

TEAM

Junior Researchers

Ana Luísa Pereira Teixeira, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-7489-2211/ 391C-0BD8-CCF0
Junior Research (PAINLESS| ID: 101057367)
E-mail: ana.luisa.teixeira@ipoporto.min.saude.pt

Other Researchers

Daniela Fonseca e Silva, MD PhD
ORCID/Ciência ID: 0000-0001-6244-9987/ EC11-510D-3FB2
Consultant in Clinical Pathology
E-mail: daniela.freitas@ipoporto.min-saude.pt

Mariana Isabel Cruz Rei, MD, PhD
ORCID/Ciência ID: 0000-0001-5974-9671 / 1918-5910-454E
Attending in Gynecology
E-mail: mariana.rei@ipoporto.min-saude.pt

Associated Researchers

Áurea Rosa Nunes Pereira Lima, MD, PhD
ORCID ID/ Ciência ID: 0000-0002-9779-0584/ A212-12E7-7E9E
Medical Oncology, Resident @ Centro Hospitalar de Entre-Douro e Vouga
E-mail: aurea.lima@chedv-min.saude.pt

Carina Sofia Teixeira Fernandes, PhD
ORCID ID/ Ciência ID: 0000-0002-8258-1448/ 5A1B-358C-C56C
Assistant Professor @ University Fernando Pessoa
E-mail: carinafernandes@ufp.edu.pt

Francisca Guilherme Carvalho Dias, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-4993-4467 / 851B-027C-DCB3
Assistant Professor @ University Fernando Pessoa
E-mail: francisca.carvalho.dias@ipoporto.min-saude.pt

Hugo Sousa, MD, PhD
ORCID ID/ CIÊNCIA ID: 0000-0001-5795-2131/ AD12-737A-17C9
Resident in Clinical Pathology @ Centro Hospitalar de Entre-Douro e Vouga
Email: hugo.sousa@ipoporto.min-saude.pt

Maria de Fátima Araújo Magalhães Cerqueira, PhD
ORCID ID/ Ciência ID: 0000-0003-4513-4654/ CF14-52ED-5DA0
Associate Professor @ University Fernando Pessoa
E-mail: fatimaf@ufp.edu.pt

Maria Raquel Silva, PhD
ORCID ID/ Ciência ID: 0000-0001-8170-3119/ 2518-6117-FB25
Associate Professor @ University Fernando Pessoa
E-mail: raquel@ufp.edu.pt

Marlene Elisabete Moreira dos Santos Lima, PhD
ORCID ID/ Ciência ID: 0000-0001-5020-5942/ 8311-B967-31C4
Coordinating Professor @ The School of Health (E2S)
Email: mes@ess.ipp.pt

Mónica Patrícia Silva Gomes, PhD
ORCID ID/ Ciência ID: 0000-0001-9947-5775/ 5B1A-9FE9-A3AA
PostDoc Researcher | Superior Technician @ Portuguese League Against Cancer – North
E-mail: monica.gomes@ligacontracancro.pt

Valéria Delgado Tavares, PhD
ORCID ID/ Ciência ID: 0000-0003-3680-7757/ B715-3863-A1DA
Assistant Professor @ University Fernando Pessoa
Email: valeria.tavares@ipoporto.min-saude.pt

Affiliated Reserachers

Rui Miguel Gil da Costa Oliveira, PhD
ORCID ID/ Ciência ID: 0000-0002-2151-2449/ 0318-98C4-ADCF
Senior Visiting Professor@ University of Maranhão
E-mail: rmcosta@fe.up.pt

PhD Students with External Funding

Supervision

Ana da Conceição Saraiva e Sousa, MSc
ORCID ID/ Ciência ID: 0000-0002-3128-3328/ AB17-B086-334A
Email: ana.tavares@ipb.pt

Andreia Filipa da Silva Rosário, MSc (FCT UI/BD/154821/2023)
ORCID ID/ Ciência ID: 0000-0003-4348-0596/ C31C-5972-87F7
Email: andreia.rosario@ipoporto.min-saude.pt

Ângela Maria Amorim Alves, MSc (FCT 2025.05389.BD, in collaboration with i3S)
ORCID/Ciência ID: 000-0002-8756-6597 / BA10-F7BE-1149
E-mail: angela.alves@ipoporto.min-saude.pt

Guido André Nchowela, MSc (FCT 2023.18580.PRT)
ORCID/Ciência ID: 0009-0001-4551-6647 / 8A1F-93D8-97AB
E-mail: nchowelag@gmail.com

Isabel Meireles, MSc (FCT 2024.04184.BDANA)
ORCID ID/ Ciência ID: 0000-0003-4513-4654/ CF14-52ED-5DA0
Email: isabeldmeireles@gmail.com

Maria Inês Dias Lopes, MSc
ORCID/Ciência ID: 0000-0002-6511-1057 / 8B10-9817-DB8D
E-mail: maria.i.lopes@ipoporto.min-saude.pt

Tânia Rôlo Dias, MSc (FCT 2022.11431.BD)
ORCID ID /Ciência ID: 0000-0002-8694-5755 / F31A-CC37-EC54
E-mail: tania.dias@ipoporto.min-saude.pt

Tiago Senosiain Mendes Ribeiro, MSc
Ciência ID: 2219-F6F1-C348
E-mail: up202301012@up.pt

Co-Supervision

Beatriz Medeiros Fonseca, MSc (in collaboration with UTAD)
ORCID ID/ Ciência ID: 0000-0002-3909-5903/ 531E-32B9-9138
E-mail: fonsecabeatriz@live.com.pt

Bruno Miguel Pinheiro Pires, MSc (FCT 2024.02748.BD, in collaboration with UBI)
ORCID/Ciência ID: 0000-0002-4181-9130 / 6A14-B2D4-7D97
E-mail: bruno.pires@ipoporto.min-saude.pt

Eduarda Almeida Rufo Pereira, MSc (FCT 2024.01697.BDANA, in collaboration with REQUIMTE LAQV)
ORCID/Ciência ID: 0000-0003-2721-7069 / 741D-D181-FD76
E-mail: eduarda.pereira@ipoporto.min-saude.pt

Izamara Gomes Maocha, MSc (FCT 2024.01697.BDANA,  in collaboration with RISE-Health)
ORCID/Ciência ID: 0000-0002-2403-7022 / 9212-DBEB-30EC
E-mail: izamaocha@gmail.com

Tiago Manuel Moreira Barbosa, MSc (FCT 2025.06124.BD, in collaboration with REQUIMTE LAQV)
ORCID/Ciência ID: 0009-0003-7654-3095 / 641B-1B5F-AB5D
E-mail: tiago.Barbosa@ipoporto.min-saude.pt

PhD Students #IPO Porto Staff

Supervision

Ana Carolina Ferreira, MD, MSc
ORCID ID/ Ciência ID: 0000-0001-5400-9447/ C913-FCA3-A39D
Email: carolina.ferreira@ipoporto.min-saude.pt

Diana Cristina Pereira Ramada, BSN, MSc (in collaborations with Clinical Oncology Group – COG)
ORCID ID/ Ciência ID: 0000-0002-4347-4471/4B11-C6D1-15D1
E-mail: diana.ramada@ipoporto.min-saude.pt

Co-Supervision

Ana Cristina Trindade Rodrigues, BSN, MSc (in collaborations with Clinical Oncology Group – COG)
ORCID ID/ Ciência ID: 0000-0002-1670-8842/ 5016-3F18-58F6
E-mail: anacrodrigues@ipoporto.min-saude.pt

José Manuel Ferrer Martinez, BSN, MSc (in collaborations with Clinical Oncology Group – COG)
ORCID ID/ Ciência ID: 0000-0002-7909-7938/ DF1B-A0A1-2302
Email: jmmartinez@ipoporto.min-saude.pt

Research Assistant/Technicians

Ana Sofia Alves Martins, BSc ((PAINLESS| ID: 101057367
ORCID/Ciência ID: 0009-0000-3987-1944 / EF1E-85C1-3E52
E-mail: ana.l.a.martins@ipoporto.min-saude.pt

Inês Cristina Guerra de Melo, BSN, MSc (LPCC NRN 2026)
ORCID/Ciência ID: 0009-0000-3839-9983 / 6E1C-2010-8371
E-mail: ines.melo@ipoporto.min-saude.pt

Mariana Filipa Couto Ferreira, MSc (LPCC NRN 2026)
ORCID/Ciência ID: 0009-0008-0220-1654 / F019-6256-EBE6
E-mail: mariana.f.ferreira@ipoporto.min-saude.pt

MSc Students

2026/2027

Supervison

Alexandra Teixeira, BSc, Master in Oncology. ICBAS-UP
Bruna Dias Machado da Silva, BSc, Master in Biochemistry in Health, E2S-UTP
Duarte Franco, BSc, Master in Medicine and Molecular Oncology, FMUP
Gonçalo Filipe Ferreira Alves, BSc Master in Metabolism – Biopathology and Experimental – FMUP
Inês Rocha, BSc Master in Laboratory Techniques in Biopathology, E2S-UTP
Matilde Gariso Godinho, BSc, Master in Clinical Laboratory Genetics, FMUC

2025/2026

Supervison

Eduarda Silva Coelho, BSc, Master in Legal Medicine, ICBAS-UP
Inês Magalhães Ferreira, BSc, Master in Oncology, ICBAS-UP

Other collaborators

Ana Teresa Meireles, BSc, Resident in Pharmacy
André Freitas Marques, MSc, Neurophysiology Technician
Carla Silva Campos, MSc, Clinical Pathology Technician
Diana Leite Russo, MSc, Resident in Medical Oncology
Filipa Duarte, MSc, Pharmacist
Inês Maria Lopes, MSc, Resident in Pharmacy
Maria Paula Silva, Consultant in Physical Medicine and Rehabilitation
Tatiana Nunes Varandas, MSc, Clinical pathology Technician

Aims

One major line of research is to try clarify the dynamic network that is established between the host and tumor microenvironment, analyzing several types of molecular biomarkers (genetic polymorphisms, mRNAs, microRNAs, LncRNAs and viral genomes) to improve our predictive capacity. The key goal of our research will be the development of rational pharmacogenomics algorithms based on a patient’s genomic profile in association with other molecular biomarkers, demographics factors, disease state, as well as other co-administered drugs to improve patient’s management using mainly a liquid biopsy and a Precision Medicine approach. Furthermore, considering the key role of several virus in oncobiology, the group also develops studies in the field of tumor virology, studying the association of viral pathogenesis (SARS-CoV, HPV, CMV and Epstein-Barr Virus) with carcinogenesis.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)
Selected publications

Tavares I, Morais M, Dias F, Medeiros R, Teixeira AL. Deregulated miRNAs in enzalutamide resistant prostate cancer: A comprehensive review of key molecular alterations and clinical outcomes. Biochim Biophys Acta Rev Cancer. 2024 Mar;1879(2):189067, doi: 10.1016/j.bbcan.2023.189067.

Rosário A, Sousa A, Varandas T, Marinho-Dias J, Medeiros R, Martins G, Monteiro P, Sousa H. Impact of cervicovaginal microbiome on the risk of cervical abnormalities development. J Med Virol. 2023;95(5):e28762, doi: 10.1002/jmv.28762

Rosário A, Sousa A, Marinho-Dias J, Medeiros R, Lobo C, Leça L, Coimbra N, Tavares F, Baldaque I, Martins G, Monteiro P, Henrique R, Sousa H. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program. J Med Virol. 2023;95(1):e28414 doi10.1002/jmv.28414

Almeida B, Dias TR, Teixeira AL, Dias F, Medeiros R. MicroRNAs Derived from Extracellular Vesicles: Keys to Understanding SARS-CoV-2 Vaccination Response in Cancer Patients? Cancers (Basel). 2023 Aug 8;15(16):4017. doi: 10.3390/cancers15164017.

Almeida C, Teixeira AL, Dias F, Morais M, Medeiros R. Extracellular Vesicles as Potential Therapeutic Messengers in Cancer Management. Biology (Basel). 2023 Apr 27;12(5):665. doi: 10.3390/biology12050665.

NATIONAL COLLABORATIONS

Adhemar Longatto, School of Life and Health Sciences at the University of Minho
Alberto Araújo, Faculty of Pharmacy of the University of Porto
Bruno Costa-Silva, Champallimaud Foundation
Fátima Barroso, ISEP | REQUIMTE LAQV
Herlander Marques, School of Life and Health Sciences at the University of Minho
João Prior, Faculty of Pharmacy of the University of Porto | REQUIMTE LAQV
José Carlos Machado, IPATIMUP/ I3S
Margarida Bastos, Department of Chemical Engineering, Faculty of Engineering, University of Porto
Paula A.M. Oliveira, Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro

 

INTERNATIONAL COLLABORATIONS

David Boutolleau, Universidade Sorbonne, UPMC Université, Centre d’Immunologie et des Maladies Infectieuses, France
Paris, France;
Jamila Perini, Escola Nacional de Saúde Pública, Fundação Oswald Cruz, Brazil
Kirsi Mikkonen, Department of Food and Nutrition Department, Faculty of Agriculture and Florestry, Helsinki University, Finland
Klaas Kok, Departamento Genética, Universidade Medical Center Groningen (UMCG), The Netherlands
Patrícia Figueiredo, Department of Food and Nutrition Department, Faculty of Agriculture and Florestry, Helsinki University, Finland
Peter S. Nelson, Fred Hutchinson Cancer Research Center (FHCRC), USA
Rui Gil da Costa, Federal University of Maranhão, Brazil

Clinical Research Unit

The Clinical Research Unit, created in the beginning of 2006 and located on the 5th floor of the Medicine Building, has the following primary objectives: attract to IPO-Porto the best Clinical Trials in the world; support their execution, monitor the compliance of the respective protocols and procedures, promoting involvement of the largest possible number of professionals in the institution. As a consequence of the work developed, supported by a professionalized team, a progressive and sustained growth of Clinical Trials and patients recruited has been registered, reducing the implementation time, with the consequent gain in competitiveness. For these reasons, IPO-Porto is currently a reference centre for Clinical Trials performed in Portugal in the large majority of pathologies treated in the institution. Being present at the highest level of Clinical Trials demands great discipline and dedication from all professionals. The Clinical Research Unit expects to maintain, in the next few years, the sustained growth in performance and encourage participation in Clinical Trials in even earlier phases (Phase I and II), namely with the creation of a specific unit for Phase I Trials. To make these objectives come true, IPO-Porto counts on the cooperation of everyone.

Oncology Nursing Research Unit

The group was established in 2022 and integrates nurses, mainly from IPO Porto, who are interested in developing research in cancer nursing. It aims to contribute to patient-centred care through the understanding of the phenomena associated with the oncological disease and its treatment, as well as its impact in patient-reported outcomes. Its mission is also to stimulate and develop research in cancer nursing at IPO Porto, through the enhancement of the skills of its professionals.

SCIENTIFIC COORDINATOR

Rui Costa, RN, MA, PhD
ORCID ID/ Ciência ID: 0000-0001-7040-3487 / 4E16-8BAA-8FA5
Specialist Nurse. Pedagogical coordinator for health education at Department of Education (EPOP). President of the Portuguese Society for the History of Nursing (SPHE)
E-mail: rui.costa@ipoporto.min-saude.pt

TEAM
Senior Researchers

Isabel Veiga Malta, PhD
ORCID ID/ Ciência ID: 0000-0002-3229-0677 / 1911-2A0A-7240
Director of the Central Sterilization Service, IPO Porto
E-mail: isabel.malta@ipoporto.min-saude.pt

Maria Esmeralda Reis Barreira, RN, MSc, PhD
ORCID ID/ Ciência ID: 0000-0001-5880-1669 / 341E-D243-5BE3
Lung Clinic Nurse Specialist, IPO Porto
E-mail: ebarreira@ipoporto.min-saude.pt

Junior Researchers

Rosa Maria Andrade Proença, PhD
ORCID ID/ Ciência ID: 6813-201C-7174 / 6813-201C-7174
Technician at Department of Education (EPOP), IPO Porto
E-mail: rosa.proenca@ipoporto.min-saude.pt

 

Associated Researchers

Ana Maria Gomes Almeida, RN, MSc
ORCID ID/ Ciência ID: 0000-0002-9725-4159 / 321E-7BD3-AD75
Adjunct Professor at Escola Superior de Saúde de Santa Maria
E-mail: ana.almeida@santamariasaude.pt

Affilliated Researchers

Bruno Magalhães, RN, PhD
ORCID ID/ Ciência ID: 0000-0001-6049-8646 / 3911-5498-3A15
Coordinating professor at the University of Trás-os-Montes e Alto Douro (UTAD)
E-mail: brunomm@utad.pt

Daniela França, RN, MSc, PhD
ORCID ID/ Ciência ID: 0000-0002-3687-8312 / D11F-BF21-66E3
Adjunct Professor at Escola Superior de Saúde de Santa Maria
E-mail: daniela.franca@santamariasaude.pt

PhD Students

Ana Cristina Rodrigues, RN, MSc, (supervised by Prof. Ana Espírito Santos – Clinical Oncoly Group – COG, Prof. Rui Medeiros – Molecular Oncology & Viral Pathology Group – OMVPG & Dr. Rui Costa, Oncology Nursing Research Unit – ONRU)
ORCID ID/ Ciência ID: 0000-0002-1670-8842 / 5016-3F18-58F6
Specialist Nurse at Nephrology Service – Hemodialysis Unit, IPO Porto
E-mail: anacrodrigues@ipoporto.min-saude.pt

Diana Ramada, RN, MSc, (supervised by Prof. Rui Medeiros – Molecular Oncology & Viral Pathology Group & Prof. Ana Espírito Santos – Clinical Oncoly Group)
ORCID ID/ Ciência ID: 0000-0002-4347-4471 / 4B11-C6D1-15D1
Specialist Nurse at the Center for Innovative Therapeutics in Oncology (CITO),
E-mail: diana.ramada@ipoporto.min-saude.pt

Luís Filipe Gonçalves da Silva, RDN, MSc, (supervised by Prof. Bruno Magalhães, Oncology Nursing Research Unit – ONRU, in collaboration with UTAD)
ORCID ID/ Ciência ID: 0000-0002-4423-7443 / 6E1A-A675-49F4
Technical Director, Project Manager and responsible for the Nutrition consultation of rare neuromuscular diseases of the Portuguese Association of Amyotrophic Lateral Sclerosis.
E-mail: flip.goncalves@gmail.com

Sara Manuela de Sousa Ferreira da Cruz, RN, MSc, (supervised by Prof. Bruno Magalhães, Oncology Nursing Research Unit – ONRU, in collaboration with UTAD)
ORCID ID/ Ciência ID: 0000-0001-7522-2802 / 6F14-F76C-AE5A
Specialist nurse at the Surgical Oncology Service, IPO Porto. Invited Adjunct Professor at Cooperativa de Ensino Superior Politécnico e Universitário (CESPU).
E-mail: sara.ferreira@ipoporto.min-saude.pt

Master Students

Catarina Mateus Bastos, BSc.
ORCID ID/ Ciência ID: 0009-0005-7032-2122 / A617-3953-16FF
Nurse at the Hematology and Bone Marrow Transplantation Service, IPO Porto.
E-mail: i13044@ipoporto.min-saude.pt

Collaborators

Ana Maria Trigo Macedo Martins, RN, MSc
ORCID ID/ Ciência ID: 0000-0002-5678-4575 / 1B11-4884-D8E6
Specialist Nurse at the Surgical Oncology Service, IPO Porto
E-mail: amaria.martins@ ipoporto.min-saude.pt

Ana Sofia Magalhães Lopes, RN, MSc.
ORCID ID/ Ciência ID: 0009-0009-1945-9368 / 6416-644A-AFC5
Specialist nurse at the Medical Oncology Service, IPO Porto
E-mail: anasofia.lopes@ipoporto.min-saude.pt

Andreia Jorge Neves Salvini Guimarães Vieira, RN, MSc
ORCID ID/ Ciência ID: 0009-0002-1767-838X / BB1D-956E-2EE5
Specialist Nurse at the Outpatient Operating Room, IPO Porto
E-mail: andreiasalvini@ipoporto.min-saude.pt

Bárbara Filipa da Silva Lamas, RN, MSc
ORCID ID/ Ciência ID: 0009-0009-9040-6568 / 3611-DC7E-1DE5
Specialist Nurse at the Day Hospital, IPO Porto
E-mail: barbara.lamas@ipoporto.min-saude.pt

Carla Regina Rodrigues da Silva, RN, MSc.
ORCID ID/ Ciência ID: 0000-0001-5147-2751 / CA1A-6620-402F
Specialist nurse at the Surgical Oncology Service, IPO Porto. Assistant Professor at Escola Superior de Saúde Norte Cruz Vermelha Portuguesa. President of the Portuguese Society of Oncology Nursing (SPEO)
E-mail: carla.silva@ipoporto.min-saude.pt

Isabel Maria Pereira da Rocha, RN, MSc.
ORCID ID/ Ciência ID: 0009-0000-3107-5310 / 2716-4FAE-EE49
Specialist nurse at the Hematology and Bone Marrow Transplantation Service, IPO Porto.
E-mail: isabel.m.rocha@ipoporto.min-saude.pt

Joana Rodrigues Lopes, RN, MSc
ORCID ID/ Ciência ID: 0009-0006-0973-9276 / F913-E4F9-3E53
Specialist nurse at the Surgical Oncology Service, IPO Porto
E-mail: joana.r.lopes@ipoporto.min-saude.pt

Manuel Jorge Freitas de Almeida, RN, MSc
ORCID ID/ Ciência ID: 0000-0001-7702-237X / 0000-0002-4423-7443
Nurse Manager at the Medical Oncology Service, IPO Porto
E-mail: jfreitas@ipoporto.min-saude.pt

Maria José Silva Dias, RN, MSc.
Specialist nurse at the Gastroenterology Service, IPO Porto.
E-mail: mjose.dias@ipoporto.min-saude.pt

Marisa Isabel Cardoso Matos, MSc.
ORCID ID/ Ciência ID: 0009-0006-5072-8595 / A418-63A8-B5A1
Nurse at the Radiology Service, IPO Porto.
E-mail: marisa.matos@ipoporto.min-saude.pt

Susana Filipa Mendes de Castro, RN, MSc,
ORCID ID/ Ciência ID: 0000-0001-8864-8634 / 3B15-857C-5FCE
Specialist nurse at the Central Surgical Service, IPO Porto. Invited Assistant Professor at Cooperativa de Ensino Superior Politécnico e Universitário (CESPU) and Escola Superior de Enfermagem do Tâmega e Sousa.
E-mail: susanafcastro@ipoporto.min-saude.pt

AIMS 

The group aims to contribute to the understanding of the processes associated with cancer disease, and to assess the impact of interventions focused on people and their families/caregivers. The priority areas of research are monitoring of complications and adherence to therapeutic regimen, digital transition and innovation, innovation in oncology and professional satisfaction and identity.

PROJECTS WITH EXTERNAL FUNDING (click to more information)
PROJECTS WITH INTERNAL FUNDING (click to more information)

 

Selected publications

Almeida, AM, Lima, L, & Martins, T. Understanding quality of life’s challenges in sarcoma patients: A mixed-methods study. European journal of oncology nursing: the official journal of European Oncology Nursing Society, 2024; 70, 102585. https://doi.org/10.1016/j.ejon.2024.102585

Cruz, S, Fernandes, C, Magalhães, B. From Hospital to Home: Health Professionals` Experiences Regarding the Needs of Palliative Patients. J Pain Symptom Manage. 2025 Sep; 70 (3): 248-257. https://doi:10.1016/j.jpainsymman.2025.05.012.

Salvini, A, Silva, E, Passos, C, Manuel, T, Moraes, C, Sousa, C, Alves, P. Validation of ELPO-PT: A Risk Assessment Scale for Surgical Positioning Injuries in the Portuguese Context. Nurs. Rep. 2024; 14, 3242–3263. https://doi.org/10.3390/ nursrep14040236

Martinez, JM, Espírito Santo, A, Ramada, D, Fontes, F, & Medeiros, R. Diagnostic accuracy of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and neutrophil-lymphocyte-to-platelet ratio biomarkers in predicting bacteremia and sepsis in immunosuppressive patients with cancer: literature review. Porto biomedical journal. 2024; 9(3), 254. https://doi.org/10.1097/j.pbj.0000000000000254

Oliveira, J, Cruz, P, Dias, TR, Sousa-Pimenta, M, Almeida, B, Soares, B, Sousa, H, Costa, R, Ochoa, C, Dias, F, & Medeiros, R. Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center. Vaccines, 2024; 12(11), 1207. https://doi.org/10.3390/vaccines12111207